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Antibodies to conserved epitopes on the HIV surface protein gp140 can protect against
infection in non-human primates, suggesting that vaccines that elicit such antibodies
would be protective. Some HIV infected individuals develop high titers of broadly
neutralizing IgG antibodies in their serum, but until recently very little was known about
the specificity and activity of these antibodies. To characterize the broadly neutralizing
memory antibody responses to HIV we cloned 1078 antibodies from HIV envelope
binding memory B cells from eight HIV infected patients with broadly neutralizing
antibodies. We found that in these patients, the B cell memory response to gp140 is
composed of up to 50 independent clones expressing high affinity antibodies to the gp120
variable loops, the CD4 binding site, the co-receptor binding site, to a new neutralizing
epitope that is in the same region of gp120 as the CD4 binding site and to gp41. In four
patients highly potent broadly neutralizing antibody clones directed to the CD4 binding
site were isolated. Despite extensive hypermutation, these broadly neutralizing CD4bs
antibodies shared a consensus sequence of 68 IgH chain amino acids and arose
independently from two related IgH genes. Thus, the IgG memory B cell compartment in
the selected group of patients with broad serum activity to HIV is comprised of multiple

clonal responses. Neutralizing activity is directed against several epitopes on gp120 with
some closely related CD4 binding site directed antibody clones showing highly potent
neutralizing activity.
For the first time, this study has attempted to systematically describe on a monoclonal
level the composition of broadly neutralizing serum activity against HIV.
The techniques and antibodies presented in this work are transforming our understanding
of possible targets and routes for HIV vaccine strategies and provide powerful tools for
possible HIV treatment approaches.

"What we want to do is remain innovative
and always keep our eyes on the disease."
Ralph Steinman
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Chapter 1
Introduction

The HIV Vaccine Problem
Since its discovery in 1981, HIV has killed over 25 million people and currently more
than 33 million humans are infected worldwide. Despite extensive research efforts over
the last three decades, a vaccine against HIV remains elusive(Karlsson Hedestam et al.,
2008; McElrath and Haynes, 2010; Moir et al., 2011; Walker and Burton, 2008). This
introduction will portray some of the main challenges in HIV vaccine design and discuss
the role of neutralizing antibodies in addressing them.
HIV Envelope
In order to allow infection, the HIV envelope protein (env) needs to interact with surface
receptors on the target cell. This makes env the main target of an HIV vaccine. Early
approaches using soluble envelope protein or inactivated virus as immunogens have not
met with the same success as for other pathogens, such as influenza. This failure roots in
HIV envelope diversity and other structural traits that still are not entirely understood.
Diversity
HIV displays a large diversity of envelope versions within each patient and in the
population(Keele et al., 2008; Salazar-Gonzalez et al., 2009; Taylor and Hammer, 2008;
Wei et al., 2003). Like other retroviruses, HIV depends on a reverse transcriptase to
amplify its genome. The HIV reverse transcriptase exhibits an exceedingly high error
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rate(Keulen et al., 1997; Roberts et al., 1988). In addition, sub-lethal levels of the human
anti-viral protein APOBEC3G might further enhance HIV diversity by introducing A-G
mutations(Keele et al., 2008; Rose and Korber, 2000; Wood et al., 2009).
Envelope Structure
Limited structural understanding of the native HIV envelope protein poses another
impediment on HIV vaccine design. So far, crystal structures are only available for
artificially stabilized forms of the envelope subunits(Cardoso et al., 2005; Chan et al.,
1997; Chen et al., 2005; Diskin et al., 2010; Kwon et al., 2012; Kwong et al., 1998;
Pancera et al., 2010; Shi et al., 2010; Weissenhorn et al., 1997). The main limitations for
crystallization of the entire HIV envelope protein are both extensive glycosylation and
structural flexibility.
However, cryo-electron microscopy images have shed some light upon the assembly of
functional envelope spikes on HIV particles(Liu et al., 2008; Mao et al., 2012; Zhu et al.,
2006). Although limited in resolution, the images show the envelope spike as a trimer of
gp120-gp41 heterodimers. The three gp41 monomers provide the transmembrane domain
and form a mushroom shaped structure at the base of the trimer(Liu et al., 2008). The
three gp120 monomers are placed on top of the gp41 base. In addition, the images
provide insight into the orientation of the gp120 variable loops 1/2 and 3, which were
deleted from previous core crystal structures. The loops seem to be oriented toward the
apex of the trimer with variable loops 1/2 stabilizing the spike using strong intermonomeric contacts(Liu et al., 2008). This is in contrast to the arrangement suggested by
an unliganded simian immunodeficiency virus (SIV) core crystal structure, which placed
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the V1/2 loops at the base of the trimer(Chen et al., 2005). The reasons for this
discrepancy are not clear and underscore the necessity for structural characterization of
diverse HIV strains in different conformational states.
High levels of diversity and limited understanding of the envelope structure pose
challenges for HIV vaccine design. But reports of broadly neutralizing serum responses
suggest that the human immune system is able to target conserved parts of the HIV
envelope(Doria-Rose, 2010; Gray et al., 2011; Mikell et al., 2011; Sather et al., 2008;
Simek et al., 2009; Stamatatos et al., 2009; Walker et al., 2010; Weiss et al., 1985; Weiss
et al., 1986). The perspective of copying such immune responses with a vaccine has
placed the characterization of broadly neutralizing antibody responses against HIV into
the centre of HIV vaccine research.
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HIV Envelope Antibody Response and Escape
HIV envelope in early infection
HIV infection most commonly is mediated by a small number of virions. Around 80% of
heterosexual transmissions are established by a single virus(Abrahams et al., 2009; Keele
et al., 2008). The rates of multiple-variant transmissions are higher among men who have
sex with men(Li et al., 2010) and in association with inflammatory genital
infection(Haaland et al., 2009). Thus, transmission seems to pose a significant bottleneck
to the virus, which is supported by early signature mutations in the envelope that might
increase infectivity. One example for such a signature mutation is the loss of a possible
N-linked glycosylation site (PNLG) at residues 413-415(Derdeyn et al., 2004;
Gnanakaran et al., 2011). After this bottleneck the viral population rapidly diversifies,
allowing formation of up to 50 versions of a single given epitope within a few weeks and
escape from early T cell mediated selective pressure(Wood et al., 2009) (Fischer et al.,
2010)
HIV envelope antibody response is delayed
The first detectable serum antibody response to HIV env arises shortly before the peak
viremia in the third week (reviewed in (Cohen et al., 2011; McMichael et al., 2010)).
Initially, this response is directed to gp41 and is believed to have little effect on early
viral dynamics(McMichael et al., 2010; Tomaras et al., 2008). Gp120 antibodies develop
after the gp41 response and are believed to preferentially target the variable loop 3(Davis
et al., 2009; Tomaras et al., 2008). In serum neutralization assays, autologous neutralizing
activity requires at least 4-14 weeks to develop. Heterologous neutralization is
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significantly delayed and therefore rarely detected within the first year of infection(Gray
et al., 2007; Liao et al., 2013; Mikell et al., 2011; Richman et al., 2003; Wei et al., 2003).
Of note, most of these observations were acquired with polyclonal serum neutralization
tests in conjunction with sequence analysis of patient envelope genes. More recent efforts
have identified antibody mediated selection pressure earlier than detectable in serum
neutralization assays by combining single envelope genome analysis with monoclonal
antibody characterization. In the patients studied, the epitopes targeted in this early
effective antibody response included the V1/2 and V3 loops and the gp120 outer domain
as well as the CD4 binding site (CD4bs)(Bar et al., 2012; Liao et al., 2013).
HIV envelope escapes from antibody pressure
HIV avoids autologous neutralization through escape mutations. This was first
demonstrated for HIV in a series of experiments that tested serum neutralizing activity
against autologous viruses from different time points. Serum was able to neutralize virus
from previous time points better than contemporaneous virus(Richman et al., 2003; Wei
et al., 2003). Escape mutations often involve PNLG's (Wei et al., 2003) (Rong et al.,
2009). As each N-linked glycan can reach the size of one entire V3 loop these mutations
lead to considerable changes on the envelope surface. This observation introduced the
model of a mobile glycan shield as a means of continuous viral escape (Wei et al., 2003).
Interestingly, escape is mediated both by loss and gain of glycosylation sites(Gnanakaran
et al., 2011; van Gils et al., 2011). Escape from neutralizing glycan-antibodies is achieved
by loss of glycan sites such as N188(Gnanakaran et al., 2011) whereas addition of other
glycan sites helps to shield targets of neutralizing activity. Other escape mechanisms in
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chronic HIV infection involve amino acid mutations and additions in the V3 and in V1/2,
which are believed to mediate neutralization resistance by shielding parts of the envelope
spike (see below and(Euler et al., 2012; Moore et al., 2009; Rong et al., 2009)).
Recently, a first study combining monoclonal anti-HIV B cell isolation and viral
envelope characterization has prospectively followed in one patient the evolution of a
broadly neutralizing antibody clone and the concomitant viral escapes (Liao et al., 2013).
In this case the interplay between constant viral escape and strong selection pressure by a
CD4bs directed antibody clone eventually lead to the development of strong heterologous
neutralization after more than 70 weeks of infection (Liao et al., 2013).
In summary, there is ample evidence for a delayed development of an effective antibody
response in HIV infection. Once mounted, this response exerts selective pressure on the
virus by following a constantly evading viral population. The recent development of high
throughput single env genome analysis combined with monoclonal antibody studies
hopefully will provide a more detailed portrait of this continuous dialogue between
antibodies and env.
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Broadly Neutralizing Sera
Definition and Frequency
Reports of neutralizing serum activity early in the epidemic (Weiss et al., 1985; Weiss et
al., 1986) were difficult to interpret because most HIV neutralization assays at that time
used T cell line adapted HIV strains. These were found to be readily neutralized and do
not reflect true primary isolates in natural infection(Li et al., 2005). The recent
development of standardized, tiered neutralization assays (Li et al., 2005) for large-scale
HIV patient screens has established that 10-30% of patients eventually develop a broadly
neutralizing antibody response against difficult to neutralize primary isolates(Doria-Rose,
2010; Gray et al., 2011; Mikell et al., 2011; Sather et al., 2008; Simek et al., 2009;
Stamatatos et al., 2009; Walker et al., 2010). 1% of patients seem to fall into a more
stringently defined category of "elite neutralizers". These sera are able to potently
neutralize more than one strain in four different clade groups of a selected panel of
isolates(Simek et al., 2009).
Factors associated with broad neutralization are unknown
Broad neutralization usually is acquired over several years(Gray et al., 2011; Sather et al.,
2009) and peaks around four years after infection. It is not understood what the clinical
relevance of broad serum neutralization in patients is, as it does not lead to viral control
or slower disease progression(Euler et al., 2010; Pereyra et al., 2008).
Also, it is not clear what causes this activity. Several studies found a correlation between
the development of broad neutralization and either low CD4 counts or high viral loads or
both(Doria-Rose et al., 2009; Gray et al., 2011; Sather et al., 2009; van Gils et al., 2009).
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One of the studies(Gray et al., 2011)only found this correlation if CD4 counts and viral
loads from set point (6 months into infection) and not from later time points were
included in the analysis. This correlation implies, that early events in infection might
influence the later development of broad neutralization. In addition, analysis of envelope
sequences from 69 patients uncovered signature sequences in env that are associated with
high or low neutralizing activity in the same patients(Gnanakaran et al., 2010). As
discussed below, the recruitment of particular germline progenitor B cells into germinal
center reactions is important for initiating the development of broadly neutralizing serum
activity. Therefore, the idea that certain viral envelopes might be more efficient in
engaging the "right" germline progenitors is an intriguing concept.
In summary, the reasons why some individuals develop broadly neutralizing serum
activity are not yet clear. However, early CD4 counts and viral loads as well as certain
viral envelope features might play a role in this evolution.
Targets of broad Neutralization
In an attempt to identify the targeted epitopes, broadly neutralizing serum samples have
been extensively characterized by serum fractionation using mutant forms of the env
protein. The results of these studies and their implications are reviewed here.
Serum fractionation studies are limited for several reasons: Firstly, they are unable to
identify monoclonal antibodies and therefore display a limited resolution. Also, it is
difficult to evaluate neutralization potency of an antibody fraction in a bulk mixture, in
which the quantitative representation of single antibody clones is unknown. Nevertheless,
these studies have provided a first insight into broadly neutralizing epitopes.
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Gp120
CD4 binding site
Paramagnetic-bead-immobilized gp120 depletes significant neutralizing activity in a
large fraction (around 50%) of broadly neutralizing sera(Binley et al., 2008; Tomaras et
al., 2011; Walker et al., 2010). Some of this activity is directed to the CD4 binding site
(CD4bs), the site of interaction between env and its main receptor on the target cell.
Since the discovery of CD4 as the main receptor for HIV infection (Dalgleish et al.,
1984; Sattentau et al., 1986)the CD4bs on gp120 has received widespread
attention(Weiss et al., 1988). In particular the observation that soluble CD4 neutralizes
HIV broadly(Smith et al., 1987), has raised the question if antibodies might structurally
mimic this interaction.
The first gp120 core crystal structure was obtained in complex with CD4 and an antibody
to the CD4 induced site (see below)(Kwong et al., 1998). This landmark study has helped
define the CD4bs on gp120. CD4 contacts the inner domain, outer domain and bridging
sheet of gp120. This contact site forms two cavities on gp120 that accommodate residues
with sequence variability. They are surrounded by highly conserved residues such as
Asp368, Glu370, Trp427 and Asp457(Kwong et al., 1998). Two of these residues, Asp368 and
Glu370 at the Phe43(CD4) cavity are also important contact sites of the neutralizing CD4bs
antibody b12(Burton et al., 1991; Wyatt et al., 1998), which confirmed that neutralizing
antibodies can target structurally conserved parts of the CD4bs (Binley et al., 2004;
Wyatt et al., 1998).
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A point mutant in one of these conserved sites, gp120D368R, was used in serum
fractionation studies(Binley et al., 2008; Li et al., 2007; Tomaras et al., 2011; Walker et
al., 2010). In some sera with gp120 directed broad neutralization, adsorption with the
mutant left neutralization unaltered. In these cases, neutralization could be mapped to the
CD4bs. Intriguingly, some of these fractions displayed potent neutralizing activity against
b12 resistant viruses (see below)(Li et al., 2007), suggesting that monoclonal CD4bs
antibodies superior to b12 might exist (see below).
CD4 induced site
The CD4 induced site (CD4i) is an epitope on gp120 that is exposed after binding of
gp120 to CD4(Sattentau et al., 1993; Thali et al., 1993) and overlaps with the coreceptor
binding site of gp120(Rizzuto et al., 1998; Wu et al., 1996). The epitope involves the
β20–β21 ribbon of the outer domain and stems of variable loops 1/2 which upon CD4
binding together form the bridging sheet(Chen et al., 2005). The epitope's conservation
among different viral strains makes it an attractive target for broad neutralization(Kwong
et al., 1998; Rizzuto et al., 1998). On the other hand, the epitope is concealed by variable
loops V1/V2 and V3(Kwong et al., 1998) and is assembled properly only after CD4
binding(Chen et al., 2005). This might explain why the best antibody of this group, 17b,
shows only limited neutralization breadth and potency against primary isolates(Seaman et
al., 2010).
The role of CD4i antibodies in broad serum neutralization could not be clearly defined by
serum fractionation. Some studies did not find significant activity to this epitope(Binley
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et al., 2008; Tomaras et al., 2011). Another study did reveal some broad CD4i activity (Li
et al., 2009)using a point mutant of the key residue, gp120I420R.
In summary, the CD4i is a conserved but well concealed epitope on gp120. Serum
fractionation might not be an appropriate tool to characterize the role of CD4i antibodies
in broad neutralization. The recent identification of CD4bs directed antibodies that are
sensitive to the CD4i point mutation gp120I420R (see below) renders this reagent
insufficient to clearly differentiate between CD4bs and CD4i directed activity. However,
CD4i antibodies in serum do neutralize broadly in the presence of CD4(Decker et al.,
2005) and are believed to maintain CD4 dependence of HIV during infection(Kolchinsky
et al., 2001).
Variable Loop V3
To directly evaluate the role of antibodies directed to variable loops V1/2 and V3, sera
with gp120 directed broad neutralization were fractionated with a gp120 core that lacks
these variable loops(Dhillon et al., 2007; Tomaras et al., 2011). The inability to adsorb
gp120 directed neutralization with gp120 core in some cases suggests that a significant
fraction of broad neutralization in those patients is directed to the variable loops (Dhillon
et al., 2007; Tomaras et al., 2011).
Next to the CD4i, the V3 loop is the second site of interaction with the coreceptor on the
target cell. Therefore it is required for viral infectivity(Cao et al., 1997) and determines
CXCR4 or CCR5 tropism(Hwang et al., 1991). 31-39 amino acids long, the loop is
divided into a base, a flexible stem and a β-hairpin tip(Huang et al., 2005). In the
unliganded state the V3 is located laterally on the trimer apex(Liu et al., 2008). It might
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contribute to inter-monomeric interactions(Liu et al., 2008) and to neutralization
sensitivity of the envelope spike. Upon binding to CD4 the loop is released from this
position and points directly towards the target cell(Liu et al., 2008). This exposed
position allows both the base and the tip of the loop to interact with the coreceptor as a
"molecular hook"(Huang et al., 2005).
The role of V3 directed antibodies in vaccine design and broad neutralization has been
heavily debated. During acute infection, V3 specific antibodies are among the first to
show autologous neutralizing activity (Davis et al., 2009; Goudsmit et al., 1988). This
observation early on in the HIV epidemic has lead to the term "principal neutralizing
domain" and has inspired several vaccination approaches(Goudsmit et al., 1988;
Javaherian et al., 1990; Javaherian et al., 1989; Zolla-Pazner et al., 2009). However,
restricted neutralizing breadth and potency of V3 directed monoclonal antibodies(Binley
et al., 2004; Gorny et al., 2004) has raised the concern, that although immunogenic, the
V3 loop might be not accessible to antibodies on difficult to neutralize primary
isolates(Hartley et al., 2005; Wu et al., 2008).
In order to assess the contribution of this class of antibodies to broadly neutralizing serum
activity, serum studies used V3 loop peptides as inhibitors in neutralization assays(Binley
et al., 2008; Dhillon et al., 2007; Li et al., 2008). This approach was justified by the
peptide specificity of the most active known V3 loop specific monoclonals (Stanfield et
al., 2004; Stanfield et al., 2006) but did not detect any broad V3 peptide specific
activity(Binley et al., 2008; Dhillon et al., 2007; Li et al., 2008). However, a recently
discovered class of broadly neutralizing antibodies bind to a conformational epitope
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involving the V3 loop (see below). Given their conformational epitope nature, these
antibodies were not detected in V3 peptide competition assays.
Overall, the newly identified antibodies have confirmed that the V3 loop indeed is
targeted by broadly neutralizing activity. However, these antibodies target
conformational epitopes rather than continuous peptides.
Variable Loops V1/2
Cryo electron microscopy images revealed that the V1/2 loops are located at the tip of the
trimer(Hu et al., 2011; Liu et al., 2008). V1/2 loop deleted trimers show a more open
structure and heterogeneity of configuration(Hu et al., 2011). This suggests that the loops
most likely contribute to gp120 inter-monomeric interactions (Hu et al., 2011). Crystal
structures of V1/2 in the context of a scaffold show that the domain folds as four
conserved anti-parallel β strands with two connecting variable and heavily glycosylated
loops(McLellan et al., 2011).
V1/2 loops are not required for viral infectivity but removal leads to increased
neutralization sensitivity toward V3 and CD4i antibodies(Cao et al., 1997; Liu et al.,
2011). Also, in the course of infection, changes in glycosylation as well as other
mutations and insertions are believed to mediate escape from autologous
neutralization(van Gils et al., 2011). Despite their important role in neutralization
sensitivity, until recently it was not known if variable loops V1/2 are targeted by broadly
neutralizing antibodies. In fact their strong glycosylation and variability suggested that
this might not be possible(Pantophlet and Burton, 2006). Similar to the serum
fractionation results obtained with V3 peptides, V1/2 derived peptides were not able to
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block broadly neutralizing serum activity(Li et al., 2008). However, recently a group of
broadly neutralizing antibodies was identified, that penetrates the glycan shield at gp120
residue N160 and also targets the base of V1/2 (see below, PG9, PG16(Walker et al.,
2009), CH01-04(Bonsignori et al., 2011), PGT141-145(Walker et al., 2011)). Following
this, several serum studies identified broadly neutralizing sera that target this region.
These experiments were performed using V loop mutant viruses and adsorption on gp120
point mutants(Tomaras et al., 2011; Walker et al., 2010). Differences among these
antibodies in their ability to bind to monomeric gp120 and point mutants suggest that
there are different approaches to target this epitope(Tomaras et al., 2011).
Gp41
After interactions of gp120 with CD4 and the coreceptor, gp41 undergoes conformational
changes that allow fusion of the virus with the target cell.
In this process, the N-terminal fusion peptide is inserted into the target cell membrane
and the two gp41 triple-stranded heptad repeat regions HR-N and HR-C are maximally
separated. This state is also referred to as the 'prehairpin intermediate'(Chan and Kim,
1998) and is targeted by the fusion inhibitor Enfuvirtide(Wild et al., 1992). The three
strands then fold back into three hairpins and form a stable six-helix bundle. This brings
the viral and target cell membranes into close proximity and establishes a stably locked
membrane pore(Markosyan et al., 2009).
Using monoclonal antibodies and polyclonal sera in ELISA based assays, five partly
overlapping binding clusters were identified as antibody targets on gp41 (reviewed in
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(Pietzsch et al., 2010b)). Of these, clusters I, II and the membrane proximal region
(clusters III and IV) have received the greatest attention.
Cluster I lies in the so-called immunodominant region between the two heptad repeat
coils. Although this epitope is accessible on pre-hairpin as well as pre-fusion states of the
gp41 molecule(Frey et al., 2008) no neutralizing antibodies to this epitope were isolated
to date. Possible explanations for this include poor epitope accessibility on the native
membrane-bound trimer and inability to inhibit fusion even after antibody
binding(Finnegan et al., 2002).
Cluster II lies in the c terminal heptad-repeat region, adjacent to the membrane proximal
region (MPER). Antibodies to this part of gp41 have also not shown broadly neutralizing
activity so far. However, the epitope might be involved in binding to the phage display
neutralizing antibody m44(Zhang et al., 2008). Although binding studies to cell surface
expressed trimers had suggested otherwise(Finnegan et al., 2002), cluster II antibodies
seem to bind to gp41 only in the postfusion conformation, which would explain their
inability to neutralize(Frey et al., 2010). Both of these studies used the same monoclonal
antibodies and the discrepancies between the results corroborate the need to understand
more about the native envelope structure in its different fusion states.
Finally, the MPER is the target of broadly neutralizing antibodies 2F5, 4E10, Z13 and
10E8 (see below and (Zwick et al., 2001a) (Huang et al., 2012; Pejchal et al., 2009)).
Inspired by the broad and potent activity of these monoclonal antibodies, serum studies
have assessed if this epitope is targeted frequently by broadly neutralizing antibodies.
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One of these studies identified three donors with broad MPER activity among 156
patients(Gray et al., 2009). This is in contrast to a recent screen of 72 neutralizing serum
samples that found a significantly higher frequency (27%) of MPER directed broadly
neutralizing activity(Huang et al., 2012).
In summary, different areas of the MPER seem to be targeted by broadly neutralizing
activity in some patients. If other parts of gp41 also are involved in broad neutralization
is not known so far. A neutralizing phage display derived antibody, m44, binds to a
conformational gp41 epitope (Zhang et al., 2008). But it is unlikely, that this antibody
was made in an immune response. Finally, our structural understanding of gp41 is still
poor. Cryo-electron microscopy studies of native trimers come to different conclusions
regarding the overall gp41 structure in a tripod configuration(Mao et al., 2012; Zhu et al.,
2006; Zhu et al., 2008) or a compact stalk(Zanetti et al., 2006). Also, although recent
crystal structures have added the MPER and fusion peptide(Buzon et al., 2010), the
integration of the MPER into the viral membrane is not well defined.
In summary, a large fraction of broadly neutralizing serum activity can be adsorbed by
gp120. In other cases, neutralizing activity is directed to the MPER or could not be
adsorbed at all. HIV neutralizing serum activity is diverse, even within single patients,
and the CD4 binding site is often targeted. However, mapping of neutralizing activity has
to be re-evaluated, since several new neutralizing conformational epitopes involving the
variable loops have been identified (see below). Also, undefined neutralizing activity still
remains a significant fraction in several cases and underscores the importance of
increasing our structural understanding of the native HIV spike.
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In the future, serum fractionation studies will be able to guide other technologies with
higher resolution. As the body of monoclonal broadly neutralizing antibodies will grow,
adsorption studies will be able to evaluate, how far we are from a complete
deconvolution of broad HIV serum neutralization.

Figure 1; HIV surface trimer with binding regions
of monoclonal broadly neutralizing antibodies.
(adapted from (Walker and Burton, 2010))
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Monoclonal HIV Neutralizing antibodies
Up to the year 2009, almost three decades of significant research efforts had yielded only
four broadly neutralizing monoclonal antibodies, 2F5, 4E10, 2G12 and b12.
2F5 and 4E10
Antibodies 2F5 and 4E10 were isolated from patient peripheral blood mononuclear cells
(PBMCs) using EBV immortalization and electrofusion(Buchacher et al., 1994; Purtscher
et al., 1994). They target adjacent, continuous epitopes on the membrane proximal region
(MPER) of gp41(Fig.1)(Muster et al., 1993; Ofek et al., 2004; Zwick et al., 2001a).
Co-crystallization of both antibodies with peptides revealed that considerable parts of the
CDR3 regions, in particular the tip, are not interacting with the respective peptide
epitopes(Cardoso et al., 2005; Ofek et al., 2004), suggesting further interactions between
the antibodies and the adjacent viral lipid membrane. This has been confirmed for 4E10
using nuclear magnetic resonance, electron paramagnetic resonance and surface plasmon
resonance(Sun et al., 2008). Also, mutation studies in 2F5 have shown, that alteration of
the hydrophobic CDR3 tip markedly reduces neutralizing activity while leaving the
affinity to the peptide epitope unchanged(Ofek et al., 2010). Together, this data places the
MPER epitopes of 2F5 and 4E10 into the context of the viral lipid membrane and might
explain in part why vaccination with gp41 has not been able to elicit this type of
antibodies yet(Dennison et al., 2009; Dennison et al., 2011; Kim et al., 2007).
However, the exceptional neutralization breadth of 4E10(Binley et al., 2004) as well as
impaired infectivity of viral escape variants(Manrique et al., 2007) reflect the
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conservation of the MPER epitope among the majority of HIV clades and thus makes it
an important vaccine target (Dennison et al., 2011).
2G12
2G12 is a monoclonal antibody directed to gp120. As antibodies 2F5 and 4E10, 2G12
was isolated from patient PBMCs using EBV transformation and electrofusion(Trkola et
al., 1996). The epitope of 2G12 lies in the "glycan shield" of the trimer (Fig. 1). A large
part of the HIV envelope spike surface (50% of its molecular weight) consists of Nlinked glycosylation sites. This "glycan shield" seems to increase and shift in the course
of infection and escape from autologous antibody responses(van Gils et al., 2011; Wei et
al., 2003; Wyatt et al., 1998; Wyatt and Sodroski, 1998). As N-linked glycosylation is
performed by the eukaryotic enzyme machinery in the endoplasmatic reticulum, these
sites are recognized as "self" by the immune system, which poses another mechanism of
viral immune evasion.
Co-crystallization of 2G12 with the disaccharide Manα1-2Man and the oligosaccharide
Man9GlcNAc2 characterized the interaction of 2G12 with its epitope and identified a
novel interlocked VH domain-swapped dimer Fab structure(Calarese et al., 2003). This
structure allows the interaction with a dimer interface region in addition to the two
classical antigen recognition sites.
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b12
In contrast to the above mentioned antibodies, b12 was isolated from an HIV patient
using random heavy and light chain pairing in a phage display library(Burton et al., 1991;
Burton et al., 1994). Therefore, structural insights derived from this antibody must be
interpreted carefully.
Despite this limitation, b12 has introduced the CD4 binding site as an important target of
broadly neutralizing serum responses (Fig. 1). Docking the crystal structure of b12 onto
gp120 in the CD4 bound conformation(Saphire et al., 2001) and direct co-crystallization
(Zhou et al., 2007)have defined a footprint of the b12 binding area on gp120.
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Application of neutralizing antibodies
Protection through transfer of neutralizing antibodies
The discovery of antibodies 2G12, 4E10, 2F5 and b12 has impacted our structural
understanding of the HIV surface trimer and pointed out possible vaccine targets.
However, their direct value as protective or therapeutic agents against HIV has also been
extensively assessed in vivo.
One of the first passive transfer studies in macaques used bulk IgG instead of monoclonal
antibodies. The polyclonal IgG had been isolated from macaques that had developed a
neutralizing response after being infected with a variety of clade B strains (Shibata et al.,
1999). Passive immunization followed by intravenous challenge with SHIVDH12 showed
that complete protection was possible but dose dependent and only conferred by IgG that
showed in vitro neutralization against the challenge virus(Shibata et al., 1999).
Protection against intravenous challenge was also achieved in macaques using HIVIG
and monoclonal antibodies 2G12 and 2F5 (Mascola et al., 1999). However, in order to
reach sterile protection, a combination of these three reagents was required and passive
immunization with either 2G12, 2F5 or HIVIG alone was not sufficient in the setting of
intravenous virus challenge(Mascola et al., 1999).
At the same time, passive transfer of monoclonal antibodies 2G12 or b12 alone mediated
protection against vaginal virus challenge(Mascola et al., 2000; Parren et al., 2001).
Finally, the vaginal application of a total of 5mg of the monoclonal antibody b12 was
able to protect 4/4 macaques against vaginal SHIV challenge(Veazey et al., 2003).

21

In summary, these studies have lent support to the model of antibody based protection
from intravenous and mucosal HIV challenge and thus invigorated efforts to find a way
to elicit these classes of antibodies with a vaccine. At the same time, high concentrations
of antibodies were required in order to reach protective levels due to the relatively limited
potency of the antibodies used. This limitation at the time diminished hopes to widely use
these antibodies as reagents in passive immunization or even reach sufficient levels by
vaccination(Mascola and Nabel, 2001).
As discussed below, the recent identification of highly potent HIV antibodies by us and
other groups has changed the potential of achieving HIV protection by vaccination or
passive immunization dramatically (Balazs et al., 2012). So far we still are far from using
these new antibodies in the clinical setting as protective reagents against HIV or even
achieving this activity by active immunization. However, the unprecedented potency and
breadth of these new reagents and modified versions thereof(Song et al., 2010) as well as
the growing number of neutralizing target epitopes make these goals significantly more
feasible as just a few years ago.
Treatment approach of established HIV infection with broadly neutralizing
antibodies
In addition to protection against viral challenge, monoclonal antibodies potentially could
offer modification or even reduction of an established HIV infection.
This was first studied in 14 antiretrovirally treated HIV infected subjects whose viral
isolates were highly sensitive to broadly neutralizing antibodies(Trkola et al., 2005).
Antibodies 2G12, 2F5 and 4E10 were passively administered over a period of 11 weeks
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during which antiretroviral treatment was paused. Overall, the mixture of antibodies was
able to delay viral rebound in 2/8 chronically infected participants(Trkola et al., 2005). In
acutely infected individuals the viral rebound was delayed in 6/6 cases(Trkola et al.,
2005), although this is hard to interpret because these cases were not internally controlled
for viral rebound without antibody treatment. Nevertheless, the more pronounced delay
of rebound in acutely infected individuals might be attributable to a less diverse viral
population in recently infected patients, leading to a reduced likelihood of preexisting
escape mutants to the respective antibodies.
There are numerous limitations to this study including the fact that b12 as one of the
more potent monoclonal antibodies known at that time was not included and plasma
levels of 2F5 and 4E10 were significantly lower than for 2G12. Resistance to 2G12 was
acquired in the majority of cases but to 2F5 and 4E10 in only 3/14 and 0/14 of the cases
respectively. Therefore, 2F5 and 4E10 might not have been present in concentrations
sufficient to exert selective pressure.
Nevertheless, this study has introduced a potential therapeutic application of broadly
neutralizing antibodies in humans and proven that this type of antibodies can exert
selective pressure in an established HIV infection.
Similar to HIV protection by passive antibody administration (see above), HIV antibody
therapy has to be completely reassessed since the recent discovery of highly potent
broadly neutralizing antibodies. First experiments in humanized mice (Klein et al.,
2012b) have yielded prolonged control of viral loads in animals treated with a
combination of 5 antibodies.

23

This finding transformed the longstanding dogma that HIV envelope spike diversity and
capacity to mutate would preclude any attempt to use it as a target in HIV antibody
treatment. Several studies are now underway to investigate how this treatment compares
to traditional HAART and if these two treatment modalities might be combined in
humans.
In summary, until 2009 three decades of intense research efforts had produced only 4
broadly neutralizing antibodies using EBV immortalization, electrofusion and phage
display libraries. These antibodies have provided some insight into possible vaccine
targets and in vivo applications of monoclonal antibodies including prevention and
treatment. However, the fact that broad neutralizing serum activity against HIV is
developed in around 10% of millions of HIV patients demanded a systematic
investigation of this activity.
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Memory B cells as a target to study HIV B cell responses
The thrust of our study was to design a way to efficiently and systematically study the B
cell response against HIV in patients with broadly neutralizing serum activity. This
would allow us to learn more about possible vaccine targets and isolate highly potent
monoclonal antibodies for possible clinical applications. For this, we started with a large
screen of 470 serum samples from HIV patients with low to intermediate viral loads. In
accordance with previous studies (Doria-Rose, 2010; Gray et al., 2011; Mikell et al.,
2011; Sather et al., 2008; Simek et al., 2009; Stamatatos et al., 2009; Walker et al., 2010)
we found that 5% of patients display broadly neutralizing serum activity. But where is
this activity generated and which cells would be appropriate to study in order to
characterize the monoclonal components of polyclonal serum activity?
Germinal Centers
Specificity and high affinity of antibodies are created in germinal center reactions(Berek
and Milstein, 1987; Eisen and Siskind, 1964; Jerne, 1951; McKean et al., 1984; Weigert
et al., 1970). Initially believed to be the anatomical site of lymphocyte production,
germinal centers change in size and mitotic activity following injection of foreign
antigens(reviewed in (Nieuwenhuis and Opstelten, 1984)). This mitotic activity was
attributed to dividing B cells(Nieuwenhuis and Opstelten, 1984), which connected
germinal center formation with the development of antigen specific B cell responses.
Somatic hypermutation and affinity maturation of immunoglobulins are key elements of
antigen specific B cell responses (Berek and Milstein, 1987; McKean et al., 1984;
Weigert et al., 1970) and are located at the site of germinal center reactions(Berek et al.,
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1991; Jacob et al., 1991b). In vivo studies(Allen et al., 2007a; Allen et al., 2007b; Hauser
et al., 2007; Schwickert et al., 2007) provided insight into the dynamic structure of the
germinal center reaction:
In the initiation of a germinal center reaction, mature naive IgM+ B cells are recruited
based on their antigen affinity and subsequently undergo several rounds of affinity
maturation of their immunoglobulin genes(Berek et al., 1991; Jacob et al., 1991a; Jacob
et al., 1991b; Nieuwenhuis and Opstelten, 1984; Victora and Nussenzweig, 2012).
Migrating back and forth between dark and light zones of the germinal center, the B cells
proliferate and mutate in the dark zone before returning to the light zone in order to bind
to antigen presented by follicular dendritic cells and receive stimulation through T helper
cells(Allen et al., 2007a; Allen et al., 2007b; Hauser et al., 2007; Schwickert et al., 2007).
After probing the affinity of the mutated B cell receptor (BCR), the B cells then return to
the dark zone for a further round of proliferation and mutation before returning to the
light zone again(Victora and Nussenzweig, 2012).
The key enzyme involved in the process of somatic hypermutation as well as class switch
recombination in the dark zone is Activation Induced Deaminase (AID), which
deaminates cytidine residues in the VDJ and switch regions of Ig genes(Neuberger et al.,
1999; Nussenzweig and Nussenzweig, 2010; Pavri and Nussenzweig, 2011). The
mutation rate of AID is approximately 10-3 per base pair per cell division and its activity
targets transcribed regions displaying ssDNA, therefore posing a potential threat to other
parts of the B cell genome(Muschen et al., 2000; Nussenzweig and Nussenzweig, 2010;
Odegard and Schatz, 2006; Pasqualucci et al., 2001; Shen et al., 1998). One could
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speculate, that AID mediated somatic hypermutation might partly explain increased rates
of B cell lymphomas during chronic infections, such as HIV(Gaidano et al., 2003).
Memory B cells
The outcome of a germinal center reaction are antibody secreting plasma cells as well as
memory B cells(Blink et al., 2005; Phan et al., 2006), both of which carry
immunoglobulins with high affinity to their antigen. Post germinal center memory B cells
are non-cycling cells that do not require stimulation by antigen in order to persist for long
periods of time(Maruyama et al., 2000). However, they expand rapidly in response to
antigen and develop into plasma cells that reside in the bone marrow and produce large
quantities of antibodies(Dorner and Radbruch, 2005, 2007).
Given their high density of specific surface Ig, memory B cells potentially are ideal
targets to investigate the B cell response against a specific antigen(Greenstein et al.,
1980; Hayakawa et al., 1987; McHeyzer-Williams et al., 1991; Scheid et al., 2009b).
Using fluorescently linked antigens, we proposed to first identify the HIV envelope
specific memory B cell response in donors with high levels of broadly neutralizing serum
activity. We then planned to use fluorescence activated cell sorting (FACS) of single
antigen specific memory B cells, followed by single cell reverse transcription and
specific immunoglobulin gene amplification(Wardemann et al., 2003). This would allow
us to analyze, clone and potentially reproduce the immunoglobulins of the HIV envelope
specific B cell population on a monoclonal level.
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Chapter 2
Broad diversity of anti-gp140 memory antibodies

Characteristics of anti-gp140 memory antibodies
We characterized the antibodies produced by memory B cells purified from the blood of
six patients with broadly neutralizing anti-HIV antibodies and viral titers ranging from
49-12,709 copies/ml. One of the patients was a non-progressor(Binley et al., 2004; Cao et
al., 1995), three were elite controllers(Binley et al., 2004; Deeks and Walker, 2007;
Walker, 2007), one a slow progressor(Binley et al., 2004; Li et al., 2007), and one was
infected two years ago(Scheid et al., 2009a).
Artificially trimerized YU2 gp140 protein composed of gp120 and cytoplasmic tail
truncated gp41 was used to identify and purify HIV specific B cells because it is believed
to resemble the envelope spike in some respects(Farzan et al., 1998; Pancera et al., 2005;
Yang et al., 2000; Yang et al., 2002; Zhu et al., 2006). Most importantly, we were able to
adsorb the anti-gp120 and -gp41 IgG antibodies in the serum of the patients with
trimerized YU2-gp140 (Fig. 2).
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Figure 2; Serum adsorption by
YU2-gp140 trimer and binding
to control monoclonal
antibodies. ELISA results of
serum IgG tested for binding to
gp140, gp120 and gp41 before
and after adsorption with YU2
gp140 trimer. Patients 1-4 are
represented in red, green, brown
and blue respectively.

Small numbers of B cells that bound the gp140 trimer were readily detected in the IgG+
memory B cell compartment in the patients but not in uninfected controls (Fig. 3a).
Individual gp140 binding memory B cells were purified by cell sorting, and Ig heavy and
light chains cloned from single cell cDNA libraries(Scheid et al., 2009b; Tiller et al.,
2008). We were able to amplify an average of 114 matching Ig heavy and light chain
genes from each of four HIV infected individuals and smaller numbers from two
others(Scheid et al., 2009a).
In contrast to random antibody cloning from memory B cells(Mietzner et al., 2008; Tiller
et al., 2007), and to the antibodies isolated from B cells that did not bind to gp140 from
the same subjects, we found many clonally related antibodies in the gp140 binding B cell
repertoire of all six HIV infected individuals (Fig. 3b and Table 1). The number of B cell
clones varied among patients from 22-50, and each clone was expanded to varying
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degrees ranging from 1-39 family members (Fig. 3b and Table 1). In all cases the
majority of the antibodies derived from gp140 binding memory B cells belonged to
clones with more than one member and in patient #2 all of the 141 antibodies were
members of 22 expanded families related by somatic mutations (see below). The finding
that most of the antibodies isolated from the four more complete patients belonged to
expanded clones suggested that we captured a significant fraction of the gp140-reactive
memory B cell repertoire.
Figure 3; Anti-gp140 antibody
cloning. a, Flow cytometry plots
of peripheral blood mononuclear
cells from four HIV patients
stained with anti-CD19 and
biotin-gp140. b, Distribution of
gp140 binders and non-binders
among all antibodies cloned. c,
Igk and Igl expression among all
gp140 binding antibodies. The
number in the center of the pie is
the number of antibodies, slices
are unique clones and
proportional to clone size. d,
gp140 binding ELISA for
antibodies from gp140 binding
cells from patient-1, -2, and nonbinders from patient 2. The red
line shows b12(Burton et al.,
1991) control, green line is a
negative control
mGO53(Wardemann et al.,
2003).
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Individual antibodies were expressed as complete IgG molecules by transfection and
tested for reactivity to gp140 by ELISA. 86% of all of the antibodies cloned from gp140
binding B cells were gp140 reactive (Fig. 3B). In contrast, none of the 51 antibodies
obtained from the non-gp140 binding memory B cells from two of the same patients were
gp140 specific (Fig. 3D and Table 1). In total, out of 501 cloned antibodies we obtained
432 antibodies that bound to gp140, and they belonged to 132 different B cell clones
(Table 1). The expanded clones of gp140 binding B cells contained antibodies that were
related by mutation with a maximum number of 66 mutations separating the individual
clonal relatives (Table 1, and see below).
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Table 1; IgH and IgL chain gene sequence information and antibody reactivity and neutralization
assay results of anti-gp140 antibodies. ND indicates not determined. The number of clone members with
100% IgH and IgL chain gene sequence homology is indicated and clonal relatives with various degrees of
somatic mutations are shown in the same color. a-e, Antibodies from gp140-reactive IgG B cells from
patients 1-6. f-g, Antibodies from gp140 non-reactive IgG B cells from patients 2 and 3
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Figure 4; Anti-gp140 antibody repertoire. Top line indicates patient number and gp140 binding.
IgGm are previously published controls(Tiller et al., 2007). Each clone is represented once
irrespective of clone size, or somatic variants. a, VH repertoire analysis. b, IgH CDR3 length. c,
Igk repertoire comparing Vk and Jk. d, Graphs show numbers of mutations per antibody for VH and
Vk grouped by patient or VH (right) grouped by epitope. Red stars indicate p values ≤0.001. P
values were calculated by comparison to the pool of gp140 non-reactive antibodies except those
below the lines, which refer to the paired samples.
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When compared to IgG antibodies derived from non-gp140 binding B cells from the
same patients or IgG+ memory B cells from historical controls(Tiller et al., 2007) the
gp140 binding antibodies were enriched for VH1(Huang et al., 2004), Igk vs. Igl, and Jk2
or Jk5 (Figs. 3c and 4a, b and c). Individual patients showed longer or more charged IgH
CDR3s but these features were not found in all of the patients (Fig. 4b). An unexpected
finding was that anti-gp140 antibodies were highly mutated when compared to nongp140 binding antibodies from the same patients or randomly cloned IgG memory
antibodies from historical controls (Fig. 4d). This difference in mutation frequency was
found for both VH and Vk and was highly significant whether we included all antibodies
or counted individual clones only a single time (Fig. 4d)(Scheid et al., 2009a). We
conclude that anti-gp140 memory B cells are highly selected post-germinal center cells
skewed to Igk and VH1 usage. The exceptionally high level of mutation found in these
antibodies may reflect chronic B cell immune responses to HIV with persistent somatic
hypermutation and selection. Previous studies have shown that re-entry of memory B
cells into germinal centers occurs in humans(Bende et al., 2007). In the case of HIV, the
immune system is confronted with a chronic and constantly mutating pathogen, which
could lead to repeated recruitment of memory cells into germinal center reactions, thus
leading to ongoing AID mediated somatic hypermutation.
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Epitopes recognized by anti-gp140 memory antibodies
To map the antigenic specificity of the gp140 binding antibodies we initially performed
ELISA experiments with purified gp120 and gp41. We found that 70% of the gp140
antibodies bound to gp120 and 30% were gp41 specific (Fig. 5a, b, and c). Thus, the
majority of the antibodies cloned from gp140 binding memory B cells in patients with
broadly neutralizing anti-HIV antibodies are directed to gp120.
Anti-gp41 antibodies were further screened against a peptide library consisting of
overlapping 15mers including the membrane proximal region that binds to two broadly
neutralizing anti-gp41 monoclonal antibodies 2F5 and 4E10(Muster et al., 1993; Zwick et
al., 2001a). None of the 131 anti-gp41 antibodies assayed bound to the membrane
proximal peptides and only five antibodies bound to peptides corresponding to the
previously reported immunodominant region of gp41(Xu et al., 1991)(Table 1). We
conclude that the majority of the gp41 antibodies produced by gp140 binding memory B
cells in patients with broad serum neutralizing activity recognize conformational
determinants and that antibodies to the membrane proximal region are difficult to detect
in the gp140 trimer binding B cells in these patients despite the fact that both 2F5 and
4E10 bind to the trimer and that the trimer adsorbs the majority of the anti-gp41
antibodies in the patients serum (Fig. 2, and (Scheid et al., 2009a)).
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Figure 5; Anti-gp140 mapping by ELISA. a, Pie charts show distribution of anti-gp120 and antigp41 antibodies. b, Pie charts show distribution of antibodies binding to CD4bs, CD4i, VL, and
gp120core (Core). c, Representative ELISA results. anti-VL, 447-52D(Gorny et al., 1992) green, 2F5
anti-gp41(Buchacher et al., 1994) blue, b12 anti-CD4bs(Burton et al., 1991) red, neg. control purple
(Wardemann et al., 2003), anti-Core 4-221 black, dashed lines: 2-59 anti-VL green, 3-384 anti-gp41
blue, 2-1262 anti-CD4bs red. d, Competition ELISA for binding to gp120; patient-1 (green), -2 (blue),
-3 (orange), and -4 (purple). Each dot indicates the IC50(Scheid et al., 2009a). Red arrow shows selfinhibitory activity. b12 black, 447-52D open circle.

The specificity of the anti-gp120 binding antibodies was further mapped using a
collection of mutant proteins: gp120D368R interferes with binding to CD4 and all known
anti-CD4 binding site (anti-CD4bs) antibodies including b12(Olshevsky et al., 1990;
Pantophlet et al., 2003; Roben et al., 1994; Thali et al., 1991); gp120I420R interferes with
CD4 induced co-receptor binding site antibodies (anti-CD4i) including 17b(Thali et al.,
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1993); gp120core lacks the variable loops (VLs) and interferes with anti-VL and CD4i
antibodies(Kwong et al., 2000; Kwong et al., 1998; Wyatt et al., 1998). Antibodies that
bound to gp120, gp120core, gp120I420R but not to gp120D368R were classified as CD4bs
directed. Similarly, those that bound to gp120, gp120I420R but not to gp120core were
classified as anti-VL antibodies, and those that bound to gp120 and gp120D368R, but not to
gp120I420R were classified as anti-CD4i antibodies. Anti-CD4bs, -CD4i, and -VL
antibodies were found in all 4 of the more complete patients but their relative
representation varied significantly between patients (Fig. 5b). Among all anti-gp140
antibodies anti-CD4bs made up 9%, anti-CD4i 16% and anti-VL 27% (Fig. 5b). All of
these antibodies were also screened for binding to a library of overlapping 15mer
peptides covering all of gp120. Only three of the anti-gp120 antibodies bound to linear
peptides and all of these bound to the region within the V3 loop that is also targeted by
the previously described antibody 447-52D(Gorny et al., 1992)(Table 1).
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Affinity of anti-gp140 antibodies
To examine the kinetic binding properties of the anti-CD4bs, -CD4i and -VL antibodies
to gp140 we performed surface plasmon resonance experiments with gp140 trimer
comparing the binding of 13 such antibodies with the b12 anti-CD4bs monoclonal
(Fig. 6 and Table 2). We found that all of the antibodies had rapid association and slow
dissociation constants with KD’s ranging from 10-8-10-11 M; b12 performed at the lower
end of the spectrum with a KD of 1.2X10-8 M (Fig. 6 and Table 2). Thus, the gp140
directed IgG memory B cells obtained from the patients studied expressed high affinity
antibodies specific for the CD4bs, the CD4i site and the VLs and there was no
immunodominant epitope.

42

Figure 6; Surface plasmon resonance measurements for interaction between selected antibodies
and gp140. Graphs show antibody dissociation curves over time. The starting concentration of gp140
was 25-50µg/ml and the different curves represent 1:2 dilutions of the starting material. The X-axis
shows time in seconds and the Y-axis shows the response rate. The antibodies are indicated above each
graph. Red squares indicate anti-CD4bs, blue circles anti-gp120core, green triangle anti-CD4i and
yellow triangle anti-VL antibodies.

Table 2; Affinity measurements of b12 and selected patient antibodies by surface plasmon
resonance. Stars indicate cases in which the sensorgrams are virtually flat during the dissociation phase.
Off-rates might therefore be even slower than the ones listed. Epitopes against which the affinities were
measured are indicated above. (M=Mol/liter; s=seconds)

43

Anti-gp120core antibodies.
In addition to anti-CD4bs, -CD4i, and -VL antibodies we found a group of antibodies that
bound to gp120, gp120core, gp120D368R, and gp120I420R that we refer to as anti-gp120core
(Fig. 7). These antibodies also bound to gp120368/370AA harboring a double mutation,
which also interferes with binding to many of the known anti-CD4bs antibodies and
CD4(Li et al., 2007; Olshevsky et al., 1990).

Figure 7; Binding of anti-gp120core antibodies to gp120, gp120D368Rand gp120D368A/E370A.
Anti-Core antibodies from patients 1-4 and 6 were tested in ELISA for their binding to YU2 gp120,
gp120D368Rand gp120D368A/E370A. Red lines indicate binding to gp120, blue to gp120D368R and
green to gp120D368A/E370A. B12 is shown as a control.
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Figure 8; Effect of deglycosylation
on BAL gp120 binding. a, Gel
electrophoresis and Coomassie blue
staining or Western blot with LCA
and DCA lectin of BAL gp120 and
aglyco-BAL-gp120. b,
Representative ELISA results
comparing binding to gp120 and
aglyco-gp120 for control antibody
2g12. The red line indicates gp120
binding and green line indicates
aglyco-gp120 reactivity. Antibody
concentration is shown on the X
axis and OD405 on the Y axis. c,
Binding to gp120 (red) or aglycogp120 (green) as measured by
ELISA under saturation conditions
for all neutralizing antibodies from
patients 1-4. Epitopes, patient
source, antibody number and
relative (see above) OD405 are
indicated. Stars show antibodies
sensitive to deglycosylation.

Anti-gp120core antibodies make up 18% of all anti-gp140 antibodies cloned from gp140
binding memory B cells varying between patients from 3-35% of the repertoire (Fig. 5b
and Table 1). In order to determine how many of these antibodies are glycan-directed we
compared binding to wild type and deglycosylated BAL gp120. None of the antigp120core antibodies were sensitive to deglycosylation (Fig. 8). Therefore, these
antibodies are not predominantly directed to sugar moieties on gp120. In addition, none
of the anti-gp120core antibodies bound to a peptide library consisting of overlapping
15mers of gp120.
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To further examine the properties of the anti-gp120core antibodies we performed inhibition
ELISA experiments using biotin labeled neutralizing antibodies to the CD4bs (b12 and 164), or CD4i (1-182), or the V3L (1-79) or a representative member of the gp120core
specific group (2-491)(Binley et al., 2004) (Fig. 5d and Table 1). As expected the results
for the two anti-CD4bs antibodies b12 and 1-64 were similar and both were inhibited by
other neutralizing anti-CD4bs antibodies but not by CD4i or VL specific antibodies (Fig.
5d). In contrast, neutralizing anti-CD4i, 1-182, was inhibited by all of the neutralizing
anti-CD4bs antibodies, but only by 50% of the other anti-CD4i (possibly due to
differences in affinity) and 29% of the anti-VL antibodies (Fig. 5d and Table 1). The
selected neutralizing anti-V3L antibody was strongly inhibited by the other anti-V3L
antibodies and not by anti-CD4bs, anti-CD4i, or other neutralizing anti-VLs that were not
V3L-NNNTRKSINIGPGRA peptide specific (Fig. 5 and Table 1). These results are
consistent with structural and physiologic data suggesting that the CD4bs is in close
proximity to the CD4i site and that the conformation of the CD4i site is dependent on the
CD4bs(Kwong et al., 1998; Liu et al., 2008; Rizzuto et al., 1998; Thali et al., 1993; Wyatt
et al., 1998).
Anti-gp120core antibodies resembled b12 and CD4bs antibodies in that they inhibited the
binding of the selected anti-gp120core, anti-CD4bs, and anti-CD4i, but they did not inhibit
binding of the anti-V3L antibody. Conversely, the 2-491 anti-gp120core antibody was
inhibited by the other anti-gp120core and the anti-CD4bs antibodies (Fig. 5d and Table 1).
However, only three out of thirteen of the anti-CD4i antibodies and none of the seven
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anti-VL antibodies inhibited binding of the anti-gp120core (Fig. 5d). The affinity of antigp120core antibodies to gp140 is similar to that of the anti-CD4bs antibodies (KD’s ranging
from 2X10-8 to 4.8X10-10 M, Fig. 6 and Table 2). In addition, both classes of antibodies
show similar affinities to gp120 and gp120core (Table 2). We conclude that anti-gp120core
antibodies recognize an immunogenic epitope in the vicinity of the CD4bs and CD4i
sites.
In a follow up study we were able to further characterize the gp120core epitope by using
screening of gp120 alanine mutants(Pietzsch et al., 2010a). ELISA binding assays with
the panel of gp120core antibodies we had isolated (Table1) revealed, that this group of
antibodies shares an epitope at the outer/inner domain junction on gp120(Pietzsch et al.,
2010a). Furthermore, in experiments using mutant BAL HIV pseudovirus this epitope
was essential for viral infectivity(Pietzsch et al., 2010a).
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HIV neutralizing activity
To examine the neutralizing activity of the memory B cell antibodies we measured their
ability to inhibit infection of TZM-bl cells by Env pseudovirus variants(Montefiori,
2005),(Binley et al., 2004). Our panel included one isolate each from clades A and C as
well as a group of clade B viruses with different levels of resistance to known
neutralizing antibodies(Li et al., 2005; Li et al., 2006; Montefiori, 2005) ranging from
tier-1 strains like SF162.LS that are easily neutralized to tier-2 strains like TRO.11 which
are not neutralized even by potent broadly neutralizing anti-CD4bs antibody b12(Li et al.,
2005)(Fig. 9 and Table 3). Although most of the antibodies were tested against the entire
panel, some that did not neutralize any of the tier 1 viruses were not tested against tier 2
viruses (Fig. 9 and Table 3). Finally, purified serum IgG from the patients was assayed on
the same viruses for comparison (Fig. 9 and Table 3). Purified IgG neutralized the
majority of strains tested, but the activity was most pronounced for the more easily
neutralized tier-1 HIV variants while high concentrations of serum IgG were required for
the more resistant strains (Fig. 9 and Table 3). Interestingly, 76% of all anti-gp120s and
none of the anti-gp41 clonal families showed neutralizing activity (Fig. 9 and Table 3).
All anti-CD4bs and 88% of all anti-gp120core antibodies showed some neutralizing
activity (Fig. 9 and Table 3).
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Figure 9; Anti-gp140 antibody neutralizing activity. Source of antibodies at the top. a, Pies show
neutralizing antibodies colored, non-neutralizers grey. Epitopes are indicated. Slices are proportional
to clone size. Number of antibodies in center. b, IC50 for individual antibodies to gp41, CD4bs,
CD4i, gp120core, VLs. Colors of dots correspond to pies above. Stars indicate control antibodies b12,
17b and 447-52D(Gorny et al., 1992). c, Neutralizing activity of pooled anti-gp140s; d, Neutralizing
activity of IgG. b, c, and d, Y axis shows the antibody concentration in mg/ml required to achieve
IC50. The individual viruses on the X axis are indicated below.
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Table 3; In vitro Tzm-bl neutralization assay. Numbers indicate IC50s for the specific monoclonal
antibody, serum IgG, or pooled antibodies in the Tzm-bl assay measuring inhibition of infection by the
indicated viral strains. X indicates activity that did not reach IC50 values at the concentration tested. ad, patients 1-4 and previously described control antibodies; e, patients 5, 6.
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Table 3
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Table 3
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Of a total of 64 independent clonal families of neutralizing antibodies 22 were antigp120core, 18 were anti-CD4bs, 16 were anti-CD4i, and 8 were anti-VL including all three
of anti-V3L antibodies (Fig. 9 and Table 3). As a group, the antibodies to the CD4bs and
gp120core showed the highest levels of neutralizing activity with rare antibodies showing
activity against the more resistant tier-2 viruses at high concentrations (Fig. 9 and Table
3). Although the anti-V3L antibodies showed cross-clade neutralizing activity, and one of
them neutralized tier-2 viruses at high concentrations, most of the anti-VL antibodies
were more restricted (Fig. 9 and Table 3). Neutralizing activity was also found in the
anti-CD4i antibodies but only three of these antibodies reached IC50 values against the
more difficult to neutralize tier-2 viruses (Fig. 9 and Table 3).
Serum antibody adsorption studies found that neutralization of tier-2 viruses was
predominantly achieved by anti-CD4bs with a smaller variable contribution from antiCD4i and un-identified antibodies. However, as mentioned above, the resolution in such
studies is limited and they cannot define the nature or number of antibodies to a specific
site(Binley et al., 2008; Dhillon et al., 2007; Li et al., 2007; Li et al., 2008; Sather et al.,
2008). We found no case where a single monoclonal antibody or class of antibodies in
memory B cells accounts for all of the neutralizing activity in serum (Fig. 9 and Table 3).
Individual antibodies showed variable levels of activity against different viruses. For
example in patient #1, the clade-C virus MW965.23 was neutralized by gp120core
antibodies 1-621 and 1-705 and VL antibody 1-79, with anti- gp120core 1-705 showing the
highest activity (Fig. 9 and Table 3). In contrast, 1-621 did not neutralize the clade-B
virus Bal.26, whereas 1-79 did and was superior to 1-705 (Fig. 9 and Table 3). Similarly
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in patient #2, the clade-A virus DJ263.8 is neutralized by anti-CD4bs 2-470, anti-VL 259 but not anti-VL antibody 2-1261, whereas the same anti-VL antibody neutralized the
clade-B tier-2 virus RHPA4259.7, but neither 2-470 nor 2-59 reached IC50 against this
virus (Fig. 9 and Table 3). In conclusion, some degree of neutralizing activity was
common among gp120 specific memory antibodies. These antibodies recognized a broad
array of epitopes and neutralizing activity was heterogeneous for different viral isolates.
Memory B cells are long-lived cells and their antibodies reflect an individuals immune
responses over time. Some of these cells differentiate into plasma cells that secrete
antibodies but the relative contribution of any given memory B cell to the plasma cell
compartment is unknown and therefore a pool of cloned memory B cell antibodies cannot
be compared directly to serum. Nevertheless, we created pools of all antibodies for each
individual patient and compared the pools to purified serum IgG for neutralization (Fig. 9
and Table 3). The pools contained equal concentrations of each of the anti-gp140 clones
irrespective of clone size (Fig. 2), potential competition for epitope binding (Fig. 5) or
neutralizing activity (Fig. 9).
Purified IgGs from all four patients studied neutralized nearly all of the tier-1 viruses and
the corresponding pools of the recombinant antibodies were also active against these
viruses (Fig. 9 and Table 3). In addition, some of the antibody pools neutralized viruses
that were not neutralized by the IgG fraction. For example, pt4 purified IgG did not
reach an IC50 against SS1196.1 or 6535.3 (tier-2), but these viruses were neutralized by
recombinant antibodies 4-42, 4-8 and 4-433 and by pooled antibodies (Fig. 9 and Table
3).
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In contrast, much higher concentrations of the patients’ serum IgG were required for tier2 neutralizing activity ranging from 49-1258 mg/ml. Consistent with the more stringent
requirements for tier 2 neutralization, only the pooled monoclonal antibodies from patient
1 and 4 reconstituted this type of activity and only at high concentrations (Fig. 9 and
Table 3). For example, RHPA4259.7 and TRO.11 were neutralized by 1.1 mg/ml of the
patient 1 pool (pool of 21 antibodies each at maximum concentration of 52 µg/ml).
Similarly, the TRO.11 virus was neutralized by the pooled antibodies from patient 4 at
1.4mg/ml (pool of 50 antibodies). In both cases individual antibodies did not reach IC50
values against these viruses but several antibodies showed low levels of activity (Fig. 9
and Table 3). In conclusion, the memory antibody compartment contains a large mixture
of anti-HIV neutralizing antibodies combinations of which can reach the breadth of
activity found in the serum but only at high concentrations.
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Discussion
Since the discovery of HIV numerous monoclonal antibodies to the envelope protein
have been produced by random cloning of heavy and light chains in phage display
libraries or by selection of antibody secreting hybridomas, but until recently only a few
highly active broadly neutralizing antibodies have been obtained(Burton et al., 2005;
Karlsson Hedestam et al., 2008; Mascola, 2007; Pantophlet and Burton, 2006; ZollaPazner, 2004). Among these b12(Burton et al., 1991), 2F5 and 4E10(Buchacher et al.,
1994; Zwick et al., 2001a), and 2G12(Trkola et al., 1996) had received the greatest
attention because of their unique breadth and potency in vitro and in vivo.
The thrust of this work was to establish a new and highly efficient way to identify and
characterize the HIV envelope specific memory B cell repertoire in patients with broadly
neutralizing antibodies. For the first time we were able to delineate comprehensively the
immunoglobulin gene features as well as size and diversity of this particular B cell
repertoire.
In contrast to previous models, we found that the antibody repertoire against env is not
limited to a few immunodominant regions but rather targets a diversity of epitopes on
gp120 and gp41. The epitopes we mapped include a new class of neutralizing antibodies
to gp120core, which targets a region at the outer /inner domain junction of gp120. This
epitope is essential for viral infectivity and thus possibly has implications in vaccine
design.
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We also found, that neutralizing activity in the HIV env directed B cell response is
diverse. If broad neutralization in these patients is achieved by targeting multiple
epitopes, then a vaccine that phenocopies such a response should also include several
epitopes.
However, only in two patients we reconstituted the neutralization breadth of purified
serum IgG, and only at high concentrations. This finding implies that we still were
missing parts of the serum antibody repertoire of these patients.
Possible reasons for this limitation include the choice of bait used in the staining and
sorting of B cells. Neutralizing activity directed to epitopes not displayed on YU2 gp140
would not be recovered with our methods. Furthermore, broadly neutralizing memory B
cells could be very rare, making a more targeted bait necessary. We did isolate many
clonally related B cells, suggesting that we captured a significant fraction of env specific
B cell clones. However, we might not have identified rare clonal members of expanded B
cell families with increased neutralizing activity.
Memory and plasma B cell compartments are intertwined and we expect to capture a
significant fraction of the serum response against HIV env by investigating memory B
cells. But so far no study has portrayed a human antigen specific B cell response with this
resolution. Therefore, differences between the antibody secreting plasma cell
compartment and the memory B cell compartment provided another possible explanation
for the lack of completely reconstructing the serum response in the investigated patients.
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A high level of somatic hypermutation is another feature of this antibody compartment.
HIV is a chronic infection with a mutating virus, and ongoing germinal center reactions
or even recall of memory B cells into germinal centers might play a role in this process.
Our approach relies on PCR amplification and therefore primer binding to supposedly
conserved elements in the immunoglobulin genes. Therefore, hypermutation of these
conserved regions could limit our ability to fully capture the B cell response in the
patients studied.
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Chapter 3
Sequence and Structural Convergence of Broad and Potent
HIV Antibodies that Mimic CD4 Binding

Introduction
In our initial studies(Scheid et al., 2008; Scheid et al., 2009a), we established a new and
highly efficient method to portrait the B cell response against the gp140 envelope protein
in patients with broadly neutralizing serum activity. One of the surprising findings in our
experiments was that the gp140 specific B cell repertoire displays high levels of somatic
hypermutation. Also, VRC01, an antibody with unusually broad and potent activity
directed to the CD4 binding site (CD4bs) shows high levels of somatic mutations that are
essential for its activity(Wu et al., 2010; Zhou et al., 2010). As mentioned above, this
high frequency of mutations is a potential impediment to antibody identification because
the mutated sequences may no longer be complementary to the primers used for
immunoglobulin gene amplification(Wardemann et al., 2003).
To avert this potential difficulty, we developed a new primer set specifically designed to
address this problem (the 5’ primer is set further upstream to avoid the mutated region)
(Fig. 10 and Table 4).
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The envelope trimer of HIV is believed to be a flexible structure(Kwon et al., 2012;
Poignard et al., 2001). Comparison of the gp120 binding of antibodies b12(Chen et al.,
2009; Dey et al., 2007; Dey et al., 2009b) and VRC01 (Wu et al., 2010; Zhou et al.,
2010)with non neutralizing antibodies directed to the CD4 binding site have suggested
that binding to gp120 in the CD4 bound conformation correlates with neutralizing
activity. To systematically study the B cell response to gp120 stabilized in the CD4
bound conformation we included such a core protein (2CC-core(Dey et al., 2009b)) in
our staining experiments. In contrast to the resurfaced protein used to clone VRC01(Wu
et al., 2010; Zhou et al., 2010), which was designed to focus on antibodies to the CD4bs,
the 2CC-core should capture additional antibodies including those specific to the CD4induced co-receptor binding site (CD4i)(Chen et al., 2005; Dey et al., 2009b).
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Primers for the identification of highly mutated antibodies
The new amplification strategy was tested by sorting single B cells from a patient with
high titers of broadly neutralizing antibodies (Pt 8) that bind to 2CC-core lacking the V13 loops (2CC-core(Chen et al., 2005; Dey et al., 2009b), Fig. 10b).
In side-by-side comparisons, the new primer set increased recovery of IgH chains when
compared to the original primer set (Fig. 11)(Wardemann et al., 2003). As expected, the
antibodies obtained with the new primer set were more mutated (Fig.11 a and c) (average
35.7 vs. 19.8 p=0.0013 and maximum 85 vs. 50 for IgH) and included clones not found
with the original primer set (Fig. 11, a and b).
Moreover, the new primers also recovered VRC01-related antibodies from cDNA
samples isolated from single cells that had been sorted with the original YU2-gp140
trimer probe(Scheid et al., 2009b; Yang et al., 2000)(Fig. 12a and b). We conclude, that
VRC01-like antibodies are captured by the YU2-gp140 trimer(Yang et al., 2000), and
that primers that are specifically designed to clone highly mutated antibodies capture a
larger fraction of HIV antibodies from the memory B cells of patients with high titers of
broadly neutralizing antibodies.

61

Figure 10; Highly mutated antibodies captured with new primers. a, Amplification strategy of
the original (above(Wardemann et al., 2003)) and new (below(Table 4)) primer sets. Red boxes
indicate the location of the first primer pair on the heavy chain immunoglobulin gene, green boxes
the location of the second primer pair in the nested PCR approach. Amplification with the new
primer set follows a semi-nested approach with the same forward primers in the first and second
PCR. b, Representative flow cytometry plots show sorting strategy on peripheral blood mononuclear
cells from Pt 8 stained with anti-CD20, anti-IgG and biotinylated 2CC-core.
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Table 4; Primers for amplification of highly mutated
Immunoglobulin V heavy chain genes. Forward priming sites are
located in the leader region of the respective VH genes and allow
amplification of highly mutated VH genes in a semi-nested protocol
with 2 reverse priming sites located in the IgG constant region.
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Figure 11; Recovery of highly mutated immunoglobulin heavy chains with specific primers. a, Side
by side comparison of new and original(Wardemann et al., 2003) primer set on 2CC-core sorted single
cells from Pt 8. Each row represents one amplified heavy chain sequence and rows with the same color
identify clonally related B cells. Red boxes and (x) in the last two columns indicate successful
amplification of IgVH genes either with the new primers (Table 4), original primers(Wardemann et al.,
2003), or both. b, Sequences from a summarized as pie chart. Clonal families are shown by differently
expanded pie slices. The two highly mutated clones that were not amplified with the original primer set
are shown in striped pie slices. c, IgVH mutations from the same experiment captured by original and
new primer sets. Each dot represents one IgVH sequence.
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Figure 12; Ig V heavy (a) and light chain (b) sequences of new VRC01 clonal members. Framework
(FR) and CDR regions are indicated. Red shading shows amino acid differences from VRC01. Contact
residues between VRC01 and gp120 are shown above as closed circles for main and side chain interactions,
open circles main chain only, and stars side chains only(Zhou et al., 2010).
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Anti-2CC-core memory antibodies from four donors
Four unrelated HIV infected individuals, showing high titers of broadly neutralizing
antibodies were examined using the 2CC-core(Scheid et al., 2011b). Two of these
individuals, Pt1 and Pt3, had been studied previously, but their cloned antibodies could
not account for their serologic activity(Scheid et al., 2009a). 576 antibodies from single
sorted B cells representing 200 different founder B cell clones that were diversified by
mutation in germinal centers were obtained from a starting population of 1.5X105 IgG+
memory B cells (Fig. 13 a and Table 5).

66

Table 5; IgH and IgL chain gene sequence, antibody reactivity, neutralization assay results for
cloned antibodies. ND indicates not determined. Letters on the right side of the table indicate close clonal
relatives shown below. Previously published antibodies(Scheid et al., 2009a) are indicated with a red star.
a-d, Antibodies from 2CC-core reactive IgG B cells from patients 1, 3, 8 and 12. The number of clone
members with 95% IgH and IgL chain gene sequence homology is indicated and clonal relatives with
various degrees of somatic mutations are shown in the same color. e, f, Antibodies from gp140 reactive IgG
B cells from patients 3 and 1. Each clone is represented once with the number of relatives indicated.
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Figure 13; 2CC-core captures CD4bs antibodies. (a and b) Top line indicates bait used for sorting,
and below the patient number. The number in the centre of the pies denotes the number of antibodies;
slices are unique clones and proportional to clone size. Membership of an antibody in a B cell clone is
determined by sequence analysis, in particular CDR3s and shared V and J genes of paired heavy and
light chain genes (Table 5). a, Pie charts show a summary of detected B cell clones irrespective of their
binding epitopes. () Indicate clones found in both YU2-gp140 and 2CC-core sorted cells. b, Pie
charts show the distribution of antibodies binding to CD4bs, CD4i, CD4ind. (equally affected by
D368R and I420R), and core (not affected by either D368R or I420R). Dashed lines indicate
antibodies that were cloned but could not be produced. c, Representative ELISAs on YU2-gp120,
mutants and 2CC-core.
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Epitopes and polyreactivity of anti-2CC-core memory antibodies
Representative members of each expanded founder B cell clone were tested for binding
to gp120 and were all positive (Fig. 13b and c and Table 5). The site of antibody binding
on the envelope spike was mapped using mutant proteins that interfere with either the
CD4bs [gp120(D368R)] (Olshevsky et al., 1990; Pantophlet et al., 2003; Thali et al.,
1991), or the CD4i site [gp120(I420R)](Thali et al., 1993). NIH45-46, which is a VRC01
variant, and antibodies 3BNC60, 8ANC131, and 12A12 (antibodies selected on the basis
of neutralizing activity, see below) (Fig. 13c and Table 5) showed binding patterns
similar to VRC01. Others, including 1B2530, and 8ANC195 could not be classified
precisely based solely on ELISA.
As expected from earlier studies on HIV envelope-specific antibodies(Mouquet et al.,
2010), 65% of the antibodies isolated using the 2CC-core were polyreactive (Fig. 14)
compared to 22.7% polyreactivity in healthy control memory B cells(Tiller et al., 2007)
and 17.3% in gp140 negative B cells from HIV positive controls(Mouquet et al., 2010).
Somatic hypermutation was likely required for development of high affinity antigen
binding and polyreactivity because reversion of 4 representative antibodies to the
corresponding germline led to complete loss of binding to YU2-gp140(Yang et al., 2000)
(Fig. 14b and Fig. 15a to c).
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Figure 14; Polyreactivity of anti-HIV
antibodies. a, ELISAs measuring the
reactivity of anti-HIV antibodies against
double-stranded DNA (dsDNA), singlestranded DNA (ssDNA), insulin and
lipopolysaccharide (LPS) were performed
and evaluated as described(Mouquet et al.,
2010; Wardemann et al., 2003). Dotted
lines represent the positive control antibody
ed38(Wardemann et al., 2003). Horizontal
lines show cut-off OD405 nm for positive
reactivity. Green and red lines show the
negative (mGO53) and low positive
(eiJB40) control antibodies,
respectively(Wardemann et al., 2003). b,
Table summarizes the reactivity against
dsDNA, ssDNA, insulin and LPS (D, S, I
and L, respectively) of all single tested
antibodies and their germline counterparts.
Colors indicate the different levels of
antibody reactivity for each antigen. Open
circles identify non polyreactive, closed
circles polyreactive antibodies. Purple text
and "GL" indicates antibodies reverted to
germline. Red stars indicate antibodies
from sort with YU2-gp140(Yang et al.,
2000). c, Representative polyreactivity
ELISAs(Mouquet et al., 2010; Wardemann
et al., 2003) with positive control antibody
ed38(Wardemann et al., 2003) shown in
black dotted lines and low positive (eiJB40)
control shown in red dotted lines.
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Figure 15; Binding and neutralization of mutated and germline antibodies. a, Binding of
selected antibodies (Table 5) and their germline versions against YU2-gp140 as measured by
ELISA. Dotted black line shows b12(Burton et al., 1991), solid blue line 3BNC60, green
8ANC192, orange 12A12 and red 1NC9 (Table 5). b, Antibody binding to YU2-gp140
measured by surface plasmon resonance (SPR). The SPR sensorgrams for antibody binding of
the selected antibodies and their germline counterparts are shown. The antibodies were tested
at concentrations ranging from 44.8 nM (light blue curve) to 700 nM (dark blue curve). RU,
response units. c, Bar graphs show the binding of the selected antibodies (Table 5) and their
germline versions to ssDNA, dsDNA, Insulin and LPS (from dark to light blue) (OD405nm)
at an antibody concentration of 1µg/ml. d, IC50 neutralization titers of the selected antibodies
and germline versions against a basic virus panel (Table 6). Colors indicate concentration at
IC50: red ≤ 0.1μg/ml; orange 0.1-1 μg/ml; yellow 1-10μg/ml; green ≥10μg/ml; white not
neutralized at any concentration tested.
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HIV neutralizing activity
HIV neutralizing activity was measured in vitro using an initial panel of 8 viruses
including 3 tier 1 Clade A, B and C, and 5 tier 2 Clade B envelope (Env) pseudovirus
variants(Li et al., 2005; Seaman et al., 2010). The neutralizing activity of the antibodies
was compared to VRC01 and purified serum IgG from the donors (Fig. 16a)(Scheid et
al., 2011b). A selection of 11 representative antibodies showing high levels of
neutralizing activity were further tested on a panel of 15 additional tier 2 Env pseudovirus
variants (Fig. 16b), including 5 viruses that are resistant to VRC01 (Fig. 16 b). 88% of all
of the antibodies tested showed some neutralizing activity and 6 clones (RU01, 08, 10,
12, 16 and NIH45-46) contained antibodies that were highly potent and broad (Fig. 16).
These clones were also the most abundant among those captured by 2CC-core in each of
the four patients studied (Fig. 13 A and Table 5). Five antibodies representing four
different broadly neutralizing founder B cell clones [Clone RU01 (3BNC117, 3BNC55)
Clone RU16 (12A12) Clone RU12 (8ANC195) and NIH45-46], were tested against an
expanded panel of 118 tier 2 viral isolates from all known clades including 32 transmitted
founder viruses (Fig. 16c and Table 7) (VRC01 had previously been tested on 82 of
these)(Wu et al., 2010). The most impressive of the new antibodies, 3BNC117 belonging
to a clone with 85 members (RU01), showed an average IC80 on a combined group of 95
tier 2 viruses of 1.4μg/ml (Table 7b).
When compared to the previously published VRC01 neutralization data only 17 of the
viruses tested were more sensitive to VRC01 than 3BNC117 and 3BNC117 showed

74

greater breadth (Fig. 16b, c and Table 7) (Wu et al., 2010). NIH45-46 a new variant of
VRC01 is more potent than VRC01 on 62 of the viruses tested but still less potent than
3BNC117 (Fig. 16, B and C and Table 7)(Wu et al., 2010). Together the new antibodies
neutralize 96% of the 118 viruses tested (Table 7). Finally, the best antibodies were
highly hypermutated, and this was essential for their breadth and potency (Fig. 15 and
Table 7).
Figure 16; Antibodies captured by 2CCcore have broad and potent HIV
neutralizing activity. a, HIV neutralizing
activity assayed on a limited panel of viruses.
Top line indicates the donor number.
Antibody clones are grouped, and individual
clonal relatives are represented by a column
grouped as in Table 6. Each row represents
one virus as indicated on the left. Colors
indicate concentration at IC50: red, ≤0.1
mg/ml; orange, 0.1-1 mg/ml; yellow, 1-10
mg/ml; green, ≥10 mg/ml; white not
neutralized at any concentration tested. ()
indicates the representatives selected for the
extended virus panel. b, HIV neutralizing
activity assayed on an extended panel of
viruses. c, Neutralization summary graph
comparing the published IC50 values of
VRC01(Zhou et al., 2010) with NIH45-46
and 3BNC117 (Tables 6 and 7). Each color
represents a different HIV Clade (black
corresponds to CRF01AE, blue to Clade B,
green to Clade G, pink to clade D, grey to
Clade CD, emerald to Clade C, brown to
Clade ACD, magenta to Clade AC, red to
Clade A and orange to CRF02AG). Length of
lines and size of circles are inversely
proportional to IC50. The distance between
the outer and inner circle as well as from the
inner circle to the center of the spiders each
span two logs in IC50 concentration.
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Table 6; Neutralizing activity of 2CC-core binding antibodies against a basic virus panel of 3 Tier 1 (Clades A, B, C) and 5 Tier 2
(Clade B) viruses. Each column represents one antibody and antibody clones are grouped for each source patient (Table 5). Tier 1 viruses
are: MW965.26 (Clade C), BaL.26 (Clade B), DJ263.8 (Clade A); Tier 2 (Clade B) viruses are: 6535.3, RHPA4259.7, TRO.11, PVO.4,
YU2.DG. Colors indicate concentration at IC50 (a-d) and IC80 (e-h): for monoclonal antibodies: red ≤ 0.1μg/ml; orange 0.1-1 μg/ml;
yellow 1-10μg/ml; green ≥10μg/ml; white not neutralized at any concentration tested. Previously published data from antibodies
B12(Burton et al., 1991; Scheid et al., 2009a; Zhou et al., 2010) and VRC01(Zhou et al., 2010) is added as control; for serum IgG: orange
10-100μg/ml; yellow >100μg/ml; white not neutralized at any concentration tested
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Table 7; Neutralizing activity of selected antibodies against an extended Tier 2 virus panel.
Colors indicate concentration at IC50 a and IC80 b: red ≤ 0.1μg/ml; orange 0.1-1 μg/ml; yellow 1-10μg/ml;
green ≥10μg/ml; white not neutralized at any concentration tested. Previously
published neutralization data from antibody VRC01 is added as control. c, Summary table of neutralizing
activity shows the % of viruses from the indicated clades neutralized <50 and <1mg/ml respectively. The
Average expresses the arithmetic mean concentrations needed to neutralize the viruses that are sensitive to
the respective antibodies.
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Anti-2CC-core antibodies in the bone marrow plasma cell compartment
Our cloning strategy captures antibodies produced by antigen binding memory B cells in
the blood, but circulating antibodies are not produced by these cells, and originate instead
from plasma cells in the bone marrow(Dorner and Radbruch, 2007). To determine
whether the antibodies cloned from memory B cells are also found in the bone marrow
plasma cell compartment, we purified plasma cells from paired bone marrow samples
from patients 3 and 8 (Fig. 17) and used PCR to specifically amplify IgVH genes from the
clones RU01 and RU10 from memory B cells in these individuals (Fig. 16a, Fig. 17a, and
Table 5). Members of these clones and large numbers of additional variants were readily
identified in the respective plasma cell samples (Fig. 17b and c). We also verified that
antibodies from clones RU01, RU08 and RU10 (Fig. 16a and Table 5) are found in serum
by mass spectrometry (Fig. 18 and Table 8).
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Figure 17; Clone specific amplification of IgG genes from CD138+ bone marrow plasma cells. a,
FACS plot showing sorting strategy for bulk sort of CD19+, CD138+ bone marrow plasma cells. (b and c)
Phylogenetic trees based on predicted amino acid sequences of members of the b, RU01 clone (Pt 3) and
c, RU10 clone (Pt 8). Antibodies that were also isolated from the peripheral memory B cell compartment
are shown in red. Clone specific primers were: for RU01
CTGCAACCGGTGTACATTCTCAAGTGCAACTGGTGC (FWRD),
CTGCAACCGGTGTACATTCTCAGGTCCATTTGTCACAG (FWRD),
TGCGAAGTCGACGCTGACGAGACAGTGACCTGC (REV),
TGCGAAGTCGACGCTGAAGAGACAATAATTTG (REV),
TGCGAAGTCGACGCTGACGAGACAATAACT (REV) and for RU10:
CTGCAACCGGTGTACATTTTCAGGGGCACTTGGTG (FWRD),
TGCGAAGTCGACGCTGAGGTGACGATGACCGTG (REV).
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Figure 18; Detection of antibodies by mass spectrometry.
(a and b) Two sample spectra of collision activated dissociation MS/MS recorded on the doubly charged
peptides HSDYCDFDVWGSGSQVIVSSASTK from 3BNC153HC a, (Table 5) and
DGLGEVAPAYLYGIDAWGQGTTVIVTSASTK from 8ANC134HC b, (Table 5). Observed b-type
fragment ions (containing the N-terminus) and y-type fragment ions (containing the C-terminus) are labeled
in the spectrum. Loss of water from fragment ions is indicated by *. Ions corresponding to the loss of water
from the parent ion are labeled in the spectrum. The complete data set for the peptides detected is shown in
Table 8. c, Amino acid sequences of 3BNC60, 1B2530 and 8ANC134 heavy chains with peptides found by
Mass Spec in red. Red dots indicate differences from respective germline sequences.
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Table 8; Antibody sequences from one expanded neutralizing clone in each (a) Pt1, (b) Pt3 and (c)
Pt8. Clone labeling as in Table 5. Peptides identified by mass spectrometry are indicated in color. The
variants marked with an asterisk are uniquely defined by one or more mass spectrometrically observed
peptides (shown in yellow). The remaining mass spectrometrically observed peptides map non-uniquely to
multiple variants as shown in red. Underlined amino acids indicate non-tryptic cleavage sites in the variants
shown. The cleavages are presumed to occur through chymotryptic cleavage or additional mutations (not
observed among the cloned variants) that place a lysine or arginine residue at these sites.
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Affinity of anti-2CC-core antibodies
To determine whether antibody affinity to gp120 is related to neutralizing activity, we
compared the binding of the highly active antibodies, selected clonal relatives and
germline reverted progenitors using Surface Plasmon Resonance (SPR) (Figs. 15, 19a, b
and 20; Table 9). The top neutralizing antibodies showed affinities (KA) ranging from
≅107-1012 (M-1) to YU2-gp140 trimers(Yang et al., 2000) and ≅107-1011 (M-1) to the 2CCcore(Dey et al., 2009b) (Fig. 16a, b and Table 9(Scheid et al., 2011b)). Consistent with
their decreased neutralizing potency and breadth, 3BNC66, 3BNC156 and 3BNC55
displayed lower affinities to the YU2-gp140 trimer than 3BNC117, but surprisingly, the
affinities of these antibodies to 2CC-core did not correlate with their neutralizing activity
(Figs. 16, 20 and Tables 6 and 8). Finally, we were unable to detect binding by any of the
germline reverted antibodies tested (Figs. 15b, 19b, and Table 9). We conclude that the
antibodies captured by the 2CC-core tend to show higher affinity to the YU2- gp140
trimer than to the 2CC-core.
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Figure 19; Binding
properties of antibodies. a,
Representative SPR
sensorgrams for binding to
YU2-gp140 and 2CC-core
by 12A12, 12A21 (Table 5)
and 12A-germline (GL)
reverted antibodies. b,
Graph shows KA for
representative antibodies
(Table 5). c, Graph shows
mean fluorescence intensity
of CD4i antibody 367(Scheid et al., 2009a)
binding to Bal expressing
293T cells after incubation
with the indicated
antibodies. Table indicates
whether or not an antibody
induces CD4i site
accessibility.
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Figure 20; Affinity of RU01 clone members (Pt 3). a, Antibody binding to YU2-gp140(Yang et al.,
2000) and 2CC-core(Dey et al., 2009b) measured by surface plasmon resonance (SPR). The SPR
sensograms for antibody binding of the selected 3BNC-antibodies are shown over time. b, Bar graphs show
the binding affinity (KA) for gp140 and 2CC-core antigens for the selected IgG antibodies shown in a, RU,
response units.

Table 9; Affinity of IgG antibodies to YU2-gp140 and 2CC-core ligands measured
by surface plasmon resonance.
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CD4 agonistic function of 2CC-core antibodies
WhenVRC01 binds to the HIV spike it produces large conformational changes that
mimic CD4 binding and expose the CD4i site(Wu et al., 2010). By contrast, the broadly
neutralizing antibody b12(Burton et al., 1991) and many other known CD4bs antibodies
do not(Moore and Sodroski, 1996). To determine whether the ability to mimic CD4 is a
shared feature of the most potent antibodies (Tables 6 and 7), we expressed two different
HIV spikes(Pietzsch et al., 2010a) on the surface of HEK 293T cells and measured CD4i
antibody binding in the presence or absence of CD4 or CD4bs antibodies (Fig. 19c). With
one exception, all of the antibodies tested resemble CD4 and VRC01 in that they
facilitate CD4i-antibody binding to one or both viral spikes (Figs. 19c and 21). The only
antibody tested that did not share this characteristic, 8ANC195, was not a traditional
CD4bs antibody in that it was equally sensitive to the D368R and I420R mutations (Fig.
13c and Table 5), and it differed from the others in its neutralization pattern (Fig. 16a and
b; and Tables 6 and 7).
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Figure 21; Effect of sCD4 or monoclonal antibodies on binding of a CD4i antibody (3-67(Scheid et al.,
2009a)) to 293T cells expressing two different HIV spikes. To characterize the newly identified
antibodies we measured changes in binding of the CD4i antibody (3-67(Scheid et al., 2009a)) in the
presence of soluble CD4 or the selected antibodies (Table 5). sCD4 or antibodies of interest were added to
(a) BAL gp160Δc or (b) YU2 gp160Δc expressing 293T cells at different concentrations (1:4 dilutions,
starting with 40μg/ml), followed by incubation with an Alexa647-labeled CD4-induced-site antibody (3-67,
red line). In addition, surface expression of gp160Δc was tested with Alexa-647-labeled 2G12(Trkola et al.,
1996) or PG16(Walker et al., 2009)(grey lines). As a reference the binding curves of 3-67(Scheid et al.,
2009a) in the presence of the CD4bs antibody VRC01(Wu et al., 2010)(blue line) and the non-HIV reactive
antibody mGO (black line(Wardemann et al., 2003)) is illustrated in all graphs.
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Sequence Conservation of CD4bs Antibodies
To determine whether highly active CD4bs antibodies share common sequence features,
we aligned the 10 best antibodies: 2 variants each from independently derived antibody
clones arising in each of the 4 patients studied and from NIH45 (Fig. 12, Fig. 22a and
b)(Wu et al., 2010). Comparison of the IgVH regions revealed a conserved consensus
sequence covering 68 IgVH residues (Fig. 22A). Interestingly, the IgVH consensus
contains 7 VRC01-gp120 contact residues, including Arg 71VRC01, which mimics the key
interaction of Arg59CD4 and Asp368gp120 (Fig. 22a) (Kwong et al., 1998; Zhou et al.,
2010). All 10 antibodies arise from only two closely related germline IgVH genes that
conserve 6 contact residues (Figs. 22a, 23a, and Table 5). The codons of the consensus
residues are highly somatically mutated in the 10 selected antibodies, however, the ratio
of replacement to silent mutations in the consensus residues ranges from 0.7 to 1.7,
whereas it is 3.5-22 in the non-consensus residues indicating that conservation of the
consensus is strongly selected (Fig. 24 and Table 10). The light chain of VRC01 makes
fewer contacts with gp120(Zhou et al., 2010). Consistent with its more limited role,
comparison of the light chain sequences of the same antibodies uncovers a less extensive
consensus covering 53 IgVL residues, which includes 3 VRC01-gp120 contact residues
(Figs. 12b and 22b). Finally, like the heavy chains, the light chains arise from a limited
set of germline genes: 2 are derived from IgK1D-33, 2 from IgK3-11, and one from
IgL1-47 (Figs. 22b, 23b, and Table 5)(Zhou et al., 2010). Interestingly, antibody
8ANC195, which differed from the others in several important respects (Figs. 13c, 16b,
and 19c, 21 and Tables 6 and 7) did not entirely conform to the consensus and did not
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arise from related heavy or light chains (Fig. 22a and b and Table 5). Thus, there is
significant sequence convergence among highly active agonistic CD4bs antibodies
(HAADs).
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Figure 22; Sequence and structural conservation of HAADs. a, Amino acid alignment of 10 selected
HAADs (Table 5), their germline genes, and 8ANC195. Residues are numbered according to the 3BNC60
structure. Framework (FR) and CDR regions are indicated. Red shading shows amino acid identity, yellow
shows biochemical similarity. 70% similarity between the 10 selected HAADs defined the consensus. The
consensus sequence is shown above, dashes in this sequence indicate non-conserved residues. Contact
residues between VRC01 and gp120 are shown above the consensus as closed circles for main and side
chain interactions, open circles main chain only, and stars side chains only(Zhou et al., 2010). (b) As in (a)
for light chains. (c, d, and e) Crystal structure of 3BNC60 Fab. c, Superimposed Cα traces of the two Fab
molecules in the 3BNC60 asymmetric unit are shown in green and red. Semi-transparent surfaces are used
to outline the heavy (cyan) and light (grey) chains. d, Superimposition of the 3BNC60 VH (red Cα trace)
and VRC01 VH (cyan Cα trace) shown with a ribbon representation of the CD4 binding loop. The salt
bridge between Arg71VRC01 and Asp368gp120 is shown as dashed lines. e, Superimposition of the 3BNC60
VL (red Cα trace). Hydrogen bonds between VRC01 and gp120 are shown as dashed lines.
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Figure 22
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Figure 23; Phylogenetic tree of (a) IgVH and (b) Ig light chain germline sequences. Red shows
position of germline genes used by highly active agonistic anti-CD4bs antibodies.
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Figure 24; Somatic hypermutation analysis of selected antibodies for (a) immunoglobulin heavy
chain gene, (b) light chain kappa and (c) light chain lambda gene sequences. Sequences are aligned
with their respective germline nucleotide sequences. Somatic mutations are shown in red letters,
additionally gray boxes designate replacement mutations. Germline amino acid sequences with star
indicating consensus residues are shown above the nucleotide alignment.
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Table 10; Replacement/Silent mutation ratios for
heavy (A) and light chain (B)
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Structural conservation of HAADs
To determine whether the structure of the antibodies in different patients is also
conserved, we solved the crystal structure of the 3BNC60 Fab to 2.65 Å resolution and
compared it to VRC01 (Fig. 22c, d and e). Superimposition of the VH domains from
3BNC60 and VRC01 in the VRC01-gp120 co-crystal structure(Zhou et al., 2010) yields a
root mean square deviation (rmsd) of 1.3 Å (calculated for 111 Cα atoms) with major
differences confined to CDR2 residues 58–65 (3BNC60 numbering). Superimposing the
structures suggests conservation of the recognition interface with gp120 (Fig. 22d). For
example, Arg723BNC60 adopts a similar conformation as Arg71VRC01, which mimics an
important salt bridge normally formed between Arg59CD4 and Asp368gp120 (5, 25).
Gln653BNC60, which corresponds to Gln64VRC01, is within the residue segment (residues 58–
65) that differs in structure from VRC01. The conformation of this region of 3BNC60,
which is involved in a lattice contact in the crystals, is likely to change upon binding
gp120, as it would clash with the CD4-binding loop on gp120. Superimposing the
3BNC60 and VRC01 VL domains yields a rmsd of 0.9Å (calculated for 95 Cα atoms)
and shows that some of gp120-contacting residues are structurally conserved (Fig. 22e);
Tyr913BNC60 and Glu903BNC60 adopt similar conformations as Tyr91VRC01 and Glu96VRC01,
which engage loop D of gp120 via polar interactions (Fig. 22e). The VH and VL domains
of the two Fabs show similar interdomain interactions and overall orientation, as
superimposition of the VH and VL domains of 3BNC60 and VRC01 yields an rmsd of
1.4 Å (calculated for 206 Cα atoms). Overall, these structural comparisons suggest that
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3BNC60 binds gp120 with the same architecture as observed for the binding of
VRC01(Zhou et al., 2010).
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Discussion
Our experiments define a class of agonistic CD4bs antibodies, HAADs, that shares IgVH
and IgVL consensus sequences including 10 of the contact residues between VRC01 and
the HIV spike (Fig. 22a and b). In five different donors, these antibodies originate from
only 2 closely related IgVH and 3 IgVL genes (Fig 22a and b). Although we cannot
exclude the possibility that using the 2CC-core as bait for single cell sorting might
introduce a selection bias, gp140 sorts performed on two of the donors did not reveal
additional broadly neutralizing antibodies (Table 5 and 6), suggesting that a significant
fraction of the CD4 binding site-directed repertoire was captured in our experiments.
Thus, the repertoire of antibodies that are available to solve the problem of broad and
potent HIV neutralization by binding to the CD4bs appears to be somewhat restricted.
Despite this restriction, HAADs account for a significant fraction of the memory B cell,
and plasma cell compartments, and the circulating IgGs in the patients tested. Therefore
HAADs are not rare, and once elicited, they contribute to the circulating antibody pool in
patients that neutralize the virus broadly. However, HAADs are not found in all patients
with high titers of broad neutralizing activity(Dhillon et al., 2007; Li et al., 2007; Walker
et al., 2009). Moreover, broad neutralization can be achieved by targeting epitopes other
than the CD4bs(Buchacher et al., 1994; Muster et al., 1993; Purtscher et al., 1994; Trkola
et al., 1996; Walker et al., 2011; Walker et al., 2009; Zwick et al., 2001a) or by
combinations of antibodies to different epitopes (Scheid et al., 2009a; Zwick et al.,
2001b), or even combination of different CD4bs antibodies (Table 7).
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The high levels of neutralizing activity displayed by HAADs appears to be correlated
with binding to a specific surface, which is similar, but not identical, to that contacted by
CD4(McClure et al., 1987; Zhou et al., 2010). Why a specific type of binding that mimics
CD4 appears to be required is not known(Wu et al., 2010); however, it has been
suggested that binding of soluble CD4, or CD4 mimetic compounds, to the HIV envelope
trimer leads to the formation of a meta-stable intermediate that decays rapidly and loses
the ability to fuse(Haim et al., 2009). We speculate that HAAD binding mimics soluble
CD4, and destabilizes the trimer. Irrespective of their mechanism of action, HAADs
might contribute to viremic control in a subset of HIV infected individuals, and may be
useful in HIV prevention or possibly even therapy because of the low concentrations
required for viral neutralization.
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Chapter 4
Discussion

Until recently our understanding of broadly neutralizing activity against HIV was very
limited. We have pioneered a new technique to investigate such responses efficiently and
with unprecedented resolution. Together with others this has given us the opportunity to
transform our understanding of HIV neutralization. This chapter will discuss
improvements of our structural view of neutralization before focusing on other features of
the neutralizing HIV B cell response.
Neutralizing Epitopes
In contrast to previous assumptions broad neutralization targets a diversity of different
epitopes on the HIV envelope. On gp120 even variable regions such as the loops V1/2
and V3 are targeted by broad neutralization. The identification of neutralizing epitopes is
far from complete and extensive analysis of more patients is required.
CD4 binding site
The CD4bs is a frequent target of highly potent broadly neutralizing responses. For
HAADs, there is a striking conservation of the immunological pathway to this activity
(Falkowska et al., 2012; Lynch et al., 2012; Scheid et al., 2011b; Wu et al., 2010; Wu et
al., 2011; Zhou et al., 2010). Remarkably, this conservation includes the repertoire of
germline sequences, which seems to be restricted to 2 heavy chain genes. We speculate,
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that specifically targeting this germline repertoire might help in vaccine design. This
could be achieved by selecting antigens with high affinity to the germline version of
HAADs.
Not all CD4bs directed broad neutralizers can be classified as HAADs. Several recently
identified broadly neutralizing CD4bs antibody clones do not act as CD4 agonists on the
surface trimer and show a different pattern of neutralization in large pseudovirus
screens(Falkowska et al., 2012; Liao et al., 2013; Scheid et al., 2011b). Not all of these
have been co-crystallized with gp120 yet and the structural definition of their epitopes
will provide insight into alternative ways of approaching the CD4bs. However, these
antibodies share with HAADs a high affinity to gp120 stabilized in the CD4 bound
conformation.
Variable loops 1/2
Single cell analysis of B cells that were selected based on their neutralizing activity rather
than their binding characteristics(Walker et al., 2009) revealed new broadly neutralizing
epitopes. Two of these antibodies, PG9 and PG16 are directed to an epitope that includes
the base of variable loops 1/2. Co-crystals of PG9 with a V1/2 scaffold proves that most
of the antibody epitope consists of a Man5GlcNAc2 residue at position 160 of gp120
(strains CAP45 and ZM109), as well as glycan residues 156 (CAP45) or 173
(ZM109)(McLellan et al., 2011). With its CDR3, antibody PG9 penetrates the glycan
shield of the envelope at position 160 and grasps the entire glycan up to the protein
proximal N-acetylglucosamine(McLellan et al., 2011). In addition to these glycan sites
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PG9 also forms hydrogen bonds as well as electrostatic interactions with strand C of
V1/V2. Other representatives of this class of antibodies were identified recently
(PG16(Walker et al., 2009), CH01-04(Bonsignori et al., 2011), PGT141-145(Walker et
al., 2011)). These antibodies compete with each other in binding assays. Also, binding as
well as neutralization of this group of antibodies depends on the N160 residue,
confirming that they target an overlapping region on the HIV envelope.
Variable loop 3
Another group of broadly neutralizing antibodies (PGT127 and PGT128(Walker et al.,
2011)) was also found to mainly interact with glycan residues. These antibodies have a
primary binding site at the Man 8/9GlcNAc2 of position N332 of the gp120 outer
domain(Pejchal et al., 2011). The secondary binding site is focused on the core
pentasaccharide attached to N301 on the V3 loop(Pejchal et al., 2011). The importance of
these residues was confirmed functionally by decreased binding and neutralization
sensitivity of point mutants(Pejchal et al., 2011). In addition to the two independent
glycan binding sites, the antibodies also interact with the C terminal V3 stem, supporting
a model of heteroligation(Mouquet et al., 2010) within one combined antibody binding
site.
Further neutralizing epitopes
As mentioned above, we and other groups are currently investigating further patients and
selection methods for single B cell analysis. These attempts will very likely uncover
further neutralizing epitopes on the envelope surface. Follow up studies on patient 3,
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from which highly potent CD4bs antibodies were isolated(Scheid et al., 2011b) have
yielded two different antibodies directed to a new epitope in the vicinity of the V3 loop
and the CD4i site (Klein et al., 2012a). Although far not as broad and potent as the
CD4bs antibodies from this donor, their activity seems to complement the CD4bs
directed neutralizing activity. In addition to introducing a further new neutralizing
epitope, this study most importantly emphasizes complementary activity of diverse
neutralizing antibodies within one patient (Bonsignori et al., 2012; Klein et al., 2012a)).
Characteristics of the B cell response
Mutations and Clone Evolution
Single cell analysis revealed characteristic molecular features of the HIV neutralizing B
cell repertoire. High levels of somatic hypermutation are required for neutralization,
because reversion leads to loss of binding and neutralizing activity in broad
neutralizers(Mouquet et al., 2010; Scheid et al., 2011b; Zhou et al., 2010) (Bonsignori et
al., 2011; Scheid et al., 2011b; Walker et al., 2011; Walker et al., 2009; Wu et al., 2010).
This is true even when only non-contact sites in the scaffolding framework regions are
reverted (Klein et al., 2013).
At the same time extensive somatic hypermutation carries the risk of a non-functional
immunoglobulin or introducing AID mediated translocations(Muschen et al., 2000;
Nussenzweig and Nussenzweig, 2010; Odegard and Schatz, 2006; Pasqualucci et al.,
2001; Shen et al., 1998). In most immune responses somatic hypermutation is limited,
because there is no selection advantage for an antigen off rate beyond the speed of
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antibody internalization(10-3-10-4s-1)(Batista and Neuberger, 1998; Foote and Eisen,
1995).
It is not clear, why so many somatic mutations are required in HIV infection and if
similar levels of mutations are achieved in other chronic infections. However, the
diversity of epitope versions in the course of chronic HIV infection (Wei et al., 2003)
might play a role. We speculate that broadly neutralizing epitopes such as the CD4bs
represent functionally conserved regions on the envelope that nevertheless undergo
constant changes. These changes might lead to recall of B cell clones into germinal
centers for further rounds of affinity maturation. It is possible that over time these recalls
lead to neutralization breadth and therefore should be copied in a sequential vaccine
approach.
In supportof of this model of "chronic" affinity maturation a recent study has tracked one
evolving CD4bs B cell clone for over 100 weeks of infection (Liao et al., 2013). Most
importantly, the authors were able to isolate several intermediate viral envelopes with
their respective binding antibody intermediates and characterized both structurally. This
is particularly exciting as combining the recently developed techniques for monoclonal
antibody investigations with viral isolation in this fashion might be a very valuable tool in
the near future to portrait numerous "maps to neutralizing serum activity".
CDR3 length and polyreactivity
Long CDR3 regions(Bonsignori et al., 2011; Cardoso et al., 2005; McLellan et al., 2011;
Ofek et al., 2004; Scheid et al., 2011b; Walker et al., 2011)as well as polyreactivity
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(Haynes et al., 2005; Mouquet et al., 2010; Scheid et al., 2011b)are further common
features of several broad neutralizers.
Extended CDR3 regions are generated during V(D)J recombination (Tonegawa,
1983)and nucleotide addition early in B cell development and to a lesser extent during
somatic hypermutation(Scheid et al., 2011b; Wilson et al., 1998).
Increased CDR3 length is associated with polyreactivity(Ichiyoshi and Casali, 1994) and
extensive single cell analysis of B cell compartments has shown that both features are
selected against during B cell maturation(Wardemann et al., 2003). This selection is
achieved by developmental checkpoints that reduce the risk of autoimmunity(Yurasov et
al., 2005). Nevertheless, long CDR3 regions are functionally important elements of
several broad neutralizers. This was shown in particular for broadly neutralizing
gp41(Cardoso et al., 2005; Ofek et al., 2004) and variable loop (McLellan et al., 2011;
Pejchal et al., 2011)directed antibodies. In addition, 45-46, one of the most broad and
potent CD4bs antibodies is a clonal member of VRC01 and acquired its additional
activity through a 4 residue insertion in the CDR3 region. The insertion leads to increased
contact with the gp120 inner domain. Overall, a large fraction of broad neutralizers
require long CDR3 regions for their activity and vaccine efforts might have to
specifically target this fraction of the B cell compartment.
Similarly, polyreactivity is selected against throughout B cell development(Scheid et al.,
2011a; Tiller et al., 2007; Wardemann et al., 2003). However, a large fraction of broadly
neutralizing antibodies are polyreactive, which might be an efficient means to address
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low antigen density on the viral surface of HIV because it allows simultaneous binding of
both Fab arms(Mouquet et al., 2010). In "heteroligation", one arm binds specifically with
high affinity to the cognate antigen, whereas the second arm binds unspecifically with a
polyreactive interaction, thereby increasing the overall binding avidity(Mouquet et al.,
2010). It is not clear, which role heteroligation plays in vivo. However, vaccine design
might attempt to mimic low density interactions in order to elicit polyreactive antibodies
with higher avidity.
Broadly neutralizing HIV antibodies can protect against infection and are produced
frequently in immune responses against this virus. Our single cell analysis has provided
valuable and long-sought insight into structural and developmental features of broad HIV
neutralization. Using the methods and antibodies described in this work, we will
hopefully be able to address how to phenocopy such a response with a vaccine. Of note,
never before has a vaccine been designed "reversely" by starting with neutralizing
antibody epitopes and generating footprints of these targets. One of the main challenges
in this approach will be the differentiation between binding and neutralizing antibodies.
Neutralization is not selected for in an immune response. Therefore, it will be necessary
to find reagents that selectively bind to and elicit neutralizing antibodies.
Another challenge will be the generation of neutralization breadth. Antigen diversity and
numerous rounds of somatic hypermutation might be involved in the generation of
breadth(Liao et al., 2013). In support of this idea, recent T cell based vaccine approaches
have successfully incorporated viral diversity(Barouch et al., 2010; Santra et al., 2010).
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Finally, in addition to providing new possible vaccine targets and maps to develop
broadly neutralizing serum activity, the growing number of broadly neutralizing
antibodies might provide us with new tools in HIV antibody therapy.
As mentioned above, early studies using the antibodies 2F5, 4E10 and 2G12 had met
with limited success. Recent experiments in humanized mouse models however suggest
that a combination of several highly potent broadly neutralizing antibodies is able to
rapidly reduce and durably control viral loads at undetectable levels without antiretroviral
treatment(Klein et al., 2012b). The prospect of transferring these findings to different
clinical settings is an additional exciting door that the investigation of broadly
neutralizing B cell responses has opened to us.
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Chapter 5
Materials and Methods

Samples. Human samples were collected after signed informed consent in accordance
with Institutional Review Board (IRB)-reviewed protocols by all participating
institutions. Patient 1 was selected from a cohort of long term non progressors followed
at the Aaron Diamond Aids Research Center, New York. Patients 2, 3, 5 and 8 were
selected from a group of elite controllers that were followed at the Ragon Institute in
Boston. Patients 1, 2, 3, 5 and 8 were selected based on their broad neutralizing serum
activity against a standard panel of HIV isolates(Li et al., 2005). Patient 12 was selected
from the Protocol G Cohort of the "International Aids Vaccine Initiative" and patients 4
and 6 from the cohort of the National Institute of Allergy and Infectious Diseases based
on broad serum neutralizing activity(Walker et al., 2010).
Staining, single-cell sorting and antibody cloning. Staining and single cell sorting of
2CC-core and gp140 specific Ig+ memory B cells was performed as previously
described(Scheid et al., 2009a; Scheid et al., 2009b; Wardemann et al., 2003). Briefly,
CD19+ B cells were enriched from peripheral blood mononuclear cells using anti human
CD19 magnetic MACS beads (Miltenyi Biotec) and subsequently stained with anti
human CD20 and anti human IgG antibodies (Becton Dickinson) as well as biotinylated
2CC-core(Dey et al., 2009b) or YU2-gp140 trimer(Yang et al., 2000) followed by
detection with streptavidin coupled phycoerythrin (PE, Beckton Dickinson). Single cells
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were sorted on a FACSAria III cell sorter (Becton Dickinson), excluding cell doublets,
into 96-well PCR plates (Denville) containing 4 μl/well of ice-cold 0.5× phosphatebuffered saline (PBS) containing 10 mM DTT, 8 U RNAsin® (Promega), 0.4 U 5′-3′
Prime RNAse Inhibitor™ (Eppendorf). Plates were sealed with Microseal® ´F` Film
(BioRad), immediately frozen on dry ice before storage at − 80 °C.
cDNA synthesis and Ig amplification were performed as previously
described(Wardemann et al., 2003) and with following modifications:
Instead of using the original primer sets(Wardemann et al., 2003), first and second
immunoglobulin specific PCRs were also carried out using the primers described in Table
4 in a semi-nested approach. In order to amplify immunoglobulin genes that are highly
somatically mutated the 5’ primers are set further upstream in the leader region to avoid
the potentially mutated region. These 5' primers (Table 4) are used in both PCR steps
with different constant region primers in each step (Fig. 10, Table 4). The cloning of
heavy and light chain PCR products into their respective expression vectors was
performed as previously described(Wardemann et al., 2003) and 100% identity of cloned
expression plasmids with the original PCR product confirmed by sequencing before
expression of the antibodies in HEK 293 cells as previously described(Wardemann et al.,
2003). Clonal relationships are identified by immunoglobulin sequence analysis.
Antibodies with shared V and J genes for heavy and light chains as well as shared CDR3
region characteristics and somatic hypermutations are considered members of an
expanded clone.
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Deglycosylation of gp120 For deglycosylation 150ug of GP120 was treated with
PNGase F (New England Biolabs) and O-glycosidase (QA Bio) in 50 mM sodium
phosphate without denaturing agents and incubated overnight at 37°C to ensue maximal
deglycosylation. Lectin blots were preformed to verify glycan removal as previously
described(Kaneko et al., 2006).
ELISAs. High-binding 96-well ELISA plates (Costar) were coated overnight with 100
ng/well of purified antigens (gp140, gp120, gp41, gp120core and 2CC-core)(Dey et al.,
2009b; Kwong et al., 1998; Yang et al., 2000) and mutant proteins (gp120 D368R, gp120
I420R) (Olshevsky et al., 1990; Pantophlet et al., 2003; Thali et al., 1993; Thali et al.,
1991)in PBS. After washing, plates were blocked 2 h with 2% BSA, 1µM EDTA, 0.05%
Tween-PBS (blocking buffer) and then incubated for 2 hours with IgG antibodies diluted
at 4 µg/ml and several consecutive 1:4 dilutions in PBS. After washing, the plates were
developed by incubation for 1 h with goat HRP-conjugated anti-human IgG (Jackson
ImmunoReseach) (at 0.8 µg/ml in blocking buffer) and by adding 100 µl of HRP
chromogenic substrate (ABTS solution, Invitrogen). Optical densities were measured at
405nm (OD405nm) using an ELISA microplate reader (Molecular Devices). Background
values given by incubation of PBS alone in coated wells were subtracted. IgG Antibodies
were tested for polyreactivity as previously described (Mouquet et al., 2010) and
considered polyreactive when they recognized at least two structurally different antigens
out of the four tested; ssDNA, dsDNA, insulin, and LPS. Threshold values for reactivity
were determined by using control antibodies mGO53 (negative), eiJB40 (low positive),
and ED38 (high positive)(Mouquet et al., 2010; Wardemann et al., 2003).
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Neutralization assays. Neutralization screens were performed as described(Montefiori,
2005). In brief, neutralization was detected as reduction in luciferase reporter gene
expression after single round infection in Tzm-bl cells. In order to rule out unspecific
antiviral activity in antibody samples MuLV (murine leukemia virus) was used as a
negative control.
Clone specific identification of bone marrow plasma cells. Bone marrow plasma cells
were stained with anti human CD138 and anti CD19 antibodies (Becton Dickinson) after
Ficoll purification of mononuclear cells from bone marrow aspirates using Ficoll-Paque
(GE Healthcare). CD138+ CD19+ human plasma cells were bulk sorted on a
FACSAriaIII cell sorter (Becton Dickinson) and RNA isolation performed on 100,000
cells using Trizol LS reagent (Invitrogen) according to the manufacturers instructions.
RNA was reverse transcribed using Superscript III reverse transcriptase (Invitrogen)
according to manufacturers instructions. cDNA was then subjected to Immunoglobulin
specific PCR as previously described(Wardemann et al., 2003) with following
modifications: 1ml of cDNA was amplified in 2 rounds of nested immunoglobulin heavy
chain clone specific PCR using first round forward leader and constant region reverse
primers (Table 4) followed by clone specific forward and reverse primers, designed based
on sequencing results from single cell analysis. PCR products were gel purified and
cloned into TOPO TA vectors (Invitrogen) according to the manufacturers instructions.
Colonies were screened by PCR with clone specific primers and sequenced.
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Surface plasmon resonance. All experiments were performed with a Biacore T100
(Biacore, Inc) in HBS-EP+ running buffer (Biacore, Inc) at 25ºC as described
previously(Mouquet et al., 2010). YU2-gp140 and 2CC-core proteins at 12.5 µg/mL were
immobilized on CM5 chips (Biacore, Inc.) by amine coupling at pH 4.5 resulting in an
immobilization level of 100 RUs. For kinetic measurements on the gp140- and 2CC-corederivatized chips, IgGs were injected through flow cells at 700 nM and 4 successive 1:2dilutions in HBS-EP+ running buffer (Biacore, Inc.) at flow rates of 40 μL/min with 3
min association and 5 min dissociation. The sensor surface was regenerated between each
experiment with a 30 second injection of 10 mM glycine-HCl pH 2.5 at a flow rate of 50
μL/min. Off rate (kd (s-1)), on rate (ka (M−1 s−1) and binding constants (KD (M) or KA (M−1)
were calculated after subtraction of backgrounds (binding to control flow cells and signal
of the HBS-EP+ running buffer) using Biacore T100 Evaluation software using the
kinetic analysis and the 1:1 binding model.
CD4i site induction. 293T cells were transfected with gp160BALΔc or gp160YU.2Δc in a
pMX-IRES-GFP construct(Pietzsch et al., 2010a) using FugeneTM6 (Roche) at a 1:2
plasmid/Fugene ratio. After 48 hours 293T cells were washed with PBS, detached with
trypsin-free cell dissociation buffer (Gibco) and resuspended at a concentration of 107
cells/ml in FACS buffer (PBS, 2 % fetal bovine serum (FBS), 2 mM EDTA). sCD4
(Progenics Pharmaceuticals, Inc.) and monoclonal antibodies were added to gp160expressing 293T cells in a 1:4 dilution series starting with a concentration of 40 µg/ml.
mGO53(Mouquet et al., 2010; Wardemann et al., 2003)is a non-polyreactive negative
control antibody that does not bind to gp160Δc . After incubation for 15 min on ice cells
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were stained for 25 min on ice with an Alexa647-labeled CD4-induced site antibody (367;(Scheid et al., 2009a)) or an Alexa647-labeled control antibody (i.e. PG16(Walker et
al., 2009) or 2G12(Trkola et al., 1996) for gp160YU.2 and 2G12(Trkola et al., 1996) for
gp160BAL). Antibody labeling was performed by using Alexa Fluor® 647 Microscale
Protein Labeling Kit (Invitrogen). Cells were analyzed on an LSRFortessa cell analyzer
(BD Bioscience).
Crystallization. The 3BNC60 IgG was expressed by transient expression in HEK293-6E
cells and the Fab fragment was prepared by papain cleavage as described(Diskin et al.,
2010). Crystallization screens were conducted at 20°C by vapor diffusion in nL sitting
drops using a Mosquito™ (TTP LabTech) crystallization robot on MRC crystallization
plates (Jena Bioscience). We combined 3BNC60 Fab at a concentration of 9.5 mg/ml
with reservoir solution in a 1:1 ratio to create 400 nL drops. Initial crystallization hits
were obtained using the PEGRx HT™ (Hampton Research) crystallization screen and
further optimized manually. Crystals suitable for data collection grew after several weeks
in 11.7% polyethylene glycol 20,000, 0.1 M sodium acetate pH 5.0, 100 mM
potassium/sodium tartrate, 20 mM lithium sulfate, 10 mM N-Cyclohexyl-2aminoethanesulfonic acid (CHES) pH 9.5 in the monoclinic space group P21 with two
Fabs in the asymmetric unit. Crystals were soaked in reservoir solution supplemented
with 15% glycerol for 2 hours before immersing in reservoir solution supplemented with
30% glycerol and flash cooling in liquid nitrogen. Diffraction data were collected at the
Stanford Synchrotron Radiation Lightsource (SSRL) beam-line 12-2 at 100 K using a
Pilatus 6M detector. Data were indexed, integrated, and scaled using XDS(Kabsch,
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2010). Molecular replacement was conducted using Phaser(McCoy et al., 2007) with the
VH and CH1 domains from the anti-tumor antibody CTM01 (PDB code 1AD9) and with
the VL and CL domains of the gp120 b13 antibody (PDB code 3IDX) as search models.
Model building and refinement to 2.65 Å resolution was done iteratively using
Phenix(Adams et al., 2010)and Coot(Emsley et al., 2010). The structure was refined
using a maximum-likelihood target function and non-crystallographic symmetry
restraints. The final model (Rwork = 20.7%; Rfree = 25.7%) includes 6478 protein atoms,
146 water molecules and 28 sugar atoms. 91.9%, 7.6% and 0.5% of the residues were in
the favored, allowed, and disallowed regions, respectively, of the Ramachandran plot.
Structural analyses and visualization were done using PyMol (The PyMOL Molecular
Graphics System, Version 1.3, Schrödinger, LLC). The 3BNC60 structure consists of
residues 3–205 for the light chain (including the first N-acetylglucosamine within an Nlinked carbohydrate attached to Asn72) and 2–217 for the heavy-chain. Residues at the
termini residues and residues 133–140 within the CH1 domain are disordered.
Mass Spectrometry. IgG was purified from serum using Protein G Sepharose (GE
Healthcare) according to the manufacturers instructions. IgGs were then digested with
immobilized papain (Pierce) and digested Fab-Fc fragment mixes incubated with
saturating quantities of biotinylated 2CC-core protein(Dey et al., 2009a). Streptavidin
coupled Dynabeads (Invitrogen) were added after incubation for 15 minutes at room
temperature and subjected to 10 rounds of washing with Phosphate Buffered Saline
(Gibco). Bound Fab fragments were eluted with lithium dodecyl sulfate buffer
(Invitrogen) at 95˚C and sample purity confirmed with SDS-polyacrylamide gel
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electrophoresis followed by silver stain or coomassie staining before analysis by mass
spectrometry.
Isolated Fab fragments were reduced with dithiothreitol, alkylated using iodoacetamide,
resolved by 1D gel electrophoresis on a 4-12% NuPAGE Novex Bis-Tris gel
(Invitrogen), and stained with Coomassie Blue (Thermo Fisher). The Fab fragments were
excised from the gel, and digested using 200ng of trypsin (Promega). The resulting
peptides were isolated using reverse phase resin (PORS 20 R2, Applied
Biosystem)(Krutchinsky et al., 2001) and eluted using an aliquot of 40% acetonitrile in
0.5% acetic acid and a second aliquot of 80% acetonitrile in 0.5% acetic acid.
Acetonitrile was removed using a speedvac (Thermo Fisher Scientific) and aliquots of the
remaining solution pressure loaded onto self-packed PicoFrit® column (New Objective,
Woburn, MA) with integrated emitter tip (360 µm O.D., 50µm I.D., 10 µm tip), packed
with 6 cm of reverse-phase C18 material (ReproSil-Pur C18-AQ, 3 µm beads from Dr.
Maisch GmbH) and interfaced to a Agilent 1200 series HPLC system (Agilent) with
either a LTQ Orbitrap XL mass spectrometer or a LTQ Orbitrap Velos mass
spectrometer (Thermo Fisher Scientific) using a home-built micro electrospray source.
The peptides were eluted into the mass spectrometer with the following gradient: 0 to 5%
B in 5min, 40% B in 125 min, 60% B in 150 min, 100% B in 165 min (A = 0.1 M acetic
acid, B = 70% acetonitrile in 0.1 M acetic acid, flow rate 90 nL/min). Both instruments
were operated in the data dependent mode and for both mass spectrometers the target
value was set to 5e5 ions and a resolution of 60,000 (at 400 m/z). For analysis on the
LTQ Orbitrap XL a full scan was followed by 8 MS/MS scans on the 8 most abundant

122

ions from that full scan. The peptides (only charge states >1) were isolated with a 2 Da
window, target window of 1e4 ions, dissociated via CAD (normalized collision energy =
35, activation Q = 0.25, activation time 30 msec) and mass analyzed in the LTQ. For
analysis on the LTQ Orbitrap Velos a full scan was followed by 10 MS/MS scans at
7,500 resolution on the 10 most abundant ions from the immediate preceding full scan.
The peptides (only charge state >2) were isolated with a 3 Da window, target window of
2e5 ions, dissociated via HCD (normalized collision energy = 40, activation time 0.100
msec) and mass analyzed in the Orbitrap. For either instrument the ions selected for
MS/MS were set on an exclusion list for 30 seconds. The resulting MS/MS spectra were
searched against the Human IPI and in-house patient specific IgG database using
Xtandem!(Craig and Beavis, 2004). Peptides were automatically compared to tryptic
peptides in the human IPI and our in-house patient specific database. Peptide hits
corresponding to patient specific IgG were manually confirmed.
Multiple sequence alignments. All multiple sequence alignments were conducted using
CLUSTALW2 with default parameters (weight matrix: GONNET for proteins and UIB
for DNA, gap open= 10, gap extension 0.1). Alignment shadings were generated using
TeXshade package.
Alignment consensus. The consensus sequences for multiple alignments were generated
based on identity and similarity between residues (≥ 70%). The amino acids were
grouped based on biochemical similarity as: FYW, ILVM, RK, DE, GA, ST and NQ.
Phylogenetic Germline Trees. The relationship between sequences was generated using
the Neighbor-Joining method(Saitou and Nei, 1987). The bootstrap consensus tree
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inferred from 1,000 replicates(Felsenstein, 1988) was taken to represent the relationship.
Branches corresponding to partitions reproduced in less than 50% bootstrap replicates are
collapsed. The percentage of replicate trees in which the associated sequence clustered
together in the bootstrap test (1,000 replicates) are shown next to the
branches(Felsenstein, 1988). The tree is drawn to scale, with branch lengths in the same
units as those of the evolutionary distances used to infer the phylogenetic tree. The
evolutionary distances were computed using the number of differences method(Kumar et
al., 1994) and are in the units of the number of amino acid differences per sequence. All
ambiguous positions were removed for each sequence pair. Evolutionary analyses were
conducted in MEGA5(Tamura et al., 2007).
R/S Ratio Calculation. DNA sequences were superposed over the protein alignments for
replacement/substitution calculation. All gap positions were removed from the analysis.
The R/S ratio analysis was conducted using Perl scripts.
Statistical analysis. P value for mutation analysis was calculated using an unpaired twotailed students t-test.
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